(* Also Presented at National Meetings)
*1. EFFECTS OF UBIQUINONE AND RELATED SUBSTANCES ON THE SECRETION OF ALDOSTERONE AND CORTISOL. Fabre, L.F., Jr., Banks, R.C., McIsaac, W.M. and Farrell, G.L., American Jonrnal of Physiology, 208:1275-1280, 1965.
2. BENZOQUINONE INHIBITION OF ADRENAL STERIODOGENESIS. Fabre, L.F., Jr., Western Reserve University Microfilms, Inc., 27:10, 1966.
3. THE NEUROHYPOPHYSIS. Farrell, G.L., Fabre, L.F., Jr. and Rauschkolb, E.W., Annnual Review of Physiology, 30:557-588, 1968.
*4. DETERMINATION OF ALDOSTERONE AND TETRAHYDROALDOSTERONE IN BLOOD BY ELECTRON CAPTURE GAS CHROMATOGRAPHY. Fabre, L.F., Jr., Fenimore, D.C., Farmer, R.W., Davis, H.W. and Farrell, G.L., Journal of Chromatographic Science, 7:632-638, 1969.
*5. QUANTITATIVE ANALYSIS OF ALDOSTERONE AND CORTISOL FROM BLOOD BY GAS CHROMATOGRAPHY AND C 14 TRACERS. Fabre, L.F., Jr., Fenimore, D.C., Farmer, R.W., Davis, H.W. and Farrell, G.L., Atomlight, 70:1-12, 1969.
6. BIPHASIC STIMULATION OF ALDOSTERONE SECRETION DURING HEMORRHAGE IN DOGS. Fabre, L.F., Jr., Farmer, R.W., Davis, H.W., McBee, G. and Farrell, G.L., Circulation Research, 24:893-900, 1969.
*7. IDENTIFICATION OF VITAMIN D IN HUMAN SKIN. Rauschkolb, F.W., Davis, H.W., Fenimore, D.C., Black, H.S. and Fabre, L.F., Jr., The Journal of Investigative Dermatology, 53(4):289-294, 1969.
8. DOES ALCOHOL INGESTION CAUSE ALDOSTERONE HYPERSECRETION? Fabre, L.F., Jr., Farmer, R.W. and Farrell, G.L., Internist Observer, 7(7):2, 1969.
*9. EFFECT OF ETHANOL ON ADRENOCORTICAL STERIOD SECRETION. Fabre, L.F., Jr., Farmer, R.W. and Davis, H.W., Advances in Mental Science III, Biological Aspects of Alcohol, M K. Roach, W. M. McIsaac and P.J. Creaven, Eds., University of Texas Press, Austin, TX, 418-445, 1970.
*10. COMPUTER ASSISTED COLUMN CALIBRATION FOR GAS-LIQUID CHROMATOGRAPHY OF BIOLOGICAL COMPOUNDS. Talbot, P., Pellizzari, E.D., Brown, J.H., Farmer, R.W. and Fabre, L.F., Jr., Advances in Chromatography, 6:86, 1970.
*11. COMPUTER ASSISTED COLUMN CALIBRATION FOR GAS-LIQUID CHROMATOGRAPHY OF BIOLOGICAL COMPOUNDS. Talbot, P., Pellizzari, E.D., Brown, J.H., Farmer, R.W. and Fabre, L.F., Jr., Journal of Chromatographic Science, 9:24-28, January, 1971.
*12. ADRENAL RESPONSE TO ALCOHOL: MINERALOCORTICOID METABOLISM. Fabre, L.F., Jr., Farmer, R W., Pellizzari, E.D. and Mendelson, J.H., Recent Advances on Studies of Alcoholism, Mello and Mendelson, Eds., Government Printing Office, 1971.
13. AN EVALUATION OF THE GAS CHROMATOGRAPHIC ANALYSIS OF PLASMA AMINO ACIDS. Pellizzari, E.D., Brown, J.H., Talbot, P., Farmer, R.W. and Fabre, L.F., Jr., Journal of Chromatographic Science, 55(2):281-289, January, 1971.
14. RESEARCH TRAINING IN ALCOHOLISM. Harris, R.T., McIsaac, W.M and Fabre, L.F., Jr., Annals New York Academy of Science, 178:43-47, 1971.
*15. METABOLIC DISEASE IN MENTAL RETARDATION - A STUDY IN TEXAS. Farrell, G.L., Johnson, R, Fabre, L.F., Jr., Farmer, R W., Pellizzari, E.D. and Stephenson, M., The Endocrine System, C. Jackson, Asst. Ed, White Plains, N.Y., 7(6):94-97, 1971.
16. AN IMPROVED PLASMA AMINO ACID PURIFICATION PROCEDURE FOR GAS-LIQUID CHROMATOGRAPHY. Pellizzari, E.D., Rising, D., Brown, J.H., Farmer, R W. and Fabre, L.F., Jr., Analytical Biochemistry, 44(1):312-316, November, 1971.
*17. A RAPID ALDOSTERONE RADIOIMMUNOASSAY. Farmer, R W., Roup, W.G., Jr., Pellizzari, E.D. and Fabre, L.F., Jr., The Journal of Clinical Endocrinology and Metabolism, 34(1):18-22, January, 1972.
18. ALDOSTERONE SECRETION IN PENTOBARBITAL - ANESTHETIZED ETHANOL-INFUSED DOGS. Fabre, L.F., Jr., Farmer, R.W., Pellizzari, E.D. and Farrell, G.L., Quarterly Journal of Studies on Alcohol, 33(2):476-484, June, 1972.
*19. HYPERLYSINURIA WITH HYPERAMMONEMIA. Brown, J.H., Fabre, L.F., Jr., Farrell, G.L. and Adams, E.D., Amer. J. Dis. Child., 124:127-132, July, 1972
*20. FAILURE OF GROWTH HORMONE TO STIMULATE GLUCAGON SECRETION. Farmer, R.W., Pellizzari, E.D., Fabre, L.F., Jr., Nonaka, K., Sugase, T. and Foa,P.P., Proc. Soc. Exp. Biol. Med., 138(2):491-493, November, 1971.
*21. BIOCHEMICAL AND METABOLIC ASPECTS OF ALCOHOLISM. Fabre, L.F., Jr., Farmer, R.W., Roach, MK., Fritchie, G.E.and mcIsaac, W.M. Annals New York Academy of Scienee, 215:346, 1973.
22. IDENTIFICATION OF LITHOCHOLIC ACID AND MEASUREMENT OF OTHER BILE ACIDS IN SERUM OF HEALTHY HUMANS. Pellizzari, E.D. O'Neil, F.S., Farmer, R W. and Fabre, L.F., Jr., Clinical Chemistry, 19(2):248-252,1973.
*23. ABNORMAL TESTOSTERONE EXCRETION IN MALE ALCOHOLIC SUBJECTS. Fabre, L.F., Jr., Liegel, J.M. Pasco, P.J. and Farmer, R.W. Quarterly Journal of Studies on Alcohol, 34(1):57, 1973.
*24. ENDOCRINE ABNORMALITIES IN MALE ALCOHOLICS SUBJECTS. Fabre, L.F., Jr., Howard, P.Y. and Farmer, R.W., Texas Medicine, 68(10):88-93, October, 1972.
*25. RADIOMMUNOSSAY FOR PLASMA ALDOSTERONE WITHOUT CHROMATOGRAPHY. Farmer, R.W., Brown, J.H., Howard, P.Y. and Fabre, L.F., Jr., The Journal of Clinical Endocrinology and Metabolism, 36:460, 1973.
26. EFFECTS OF ALCOHOL ON PLASMA TESTOSTERONE, SEX HORMONE-BINDING GLOBULIN AND 17-KETOSTERIODS IN CHRONIC ALCOHOLIC AND NORMAL SUBJECTS. Farmer, R.W., Liegel, J., Howard, P.Y. and Fabre, L.F., Jr., Psychopharmacologia.
*27. BASIC AMINO ACID TRANSPORT IN HYPERLYSINURIA, Brown, J.H., Farrell, G.L. and Fabre, L.F., Jr., Pediat. Rsch.
*28. PILOT OPEN-LABEL STUDY ON U-28, 774 IN ANXIOUS IN-PATIENTS. Fabre, L.F., Jr. and Harris, R.T., Current Therapeutic Research, 16(8):848-852, August, 1974.
29. PILOT OPEN-LABEL STIJDY ON U-31, 889 IN ANXIOUS IN-PATIENTS. Fabre, L.F., Jr. and Harris, R.T., Current Therapeutic Research, 16(9):1010-1013, September, 1974.
30. SOME ENDOCRINE ASPECTS OF ALCOHOLISM. Farmer, R.W. and Fabre, L.F., Jr., Adv. Exp. Med. Biol., 16(8):848-852, 1974.
31. METABOLIC AND ENDOCRINE ASPECTS OF ALCOHOLISM. Fabre, L.F., Jr., Alc. Prob. in a Drinking Society, W.L. Gideon, Ed, Continuing Education Center, University of Houston, Houston, Texas. 96-114, 1975.
32. AN ANALYSIS OF CLINICAL FACTORS IN THE ABUSE POTENTIAL OF NEW ANTI-ANXIETY AND ANTI-DEPRESSANT DRUGS. Fabre, L.F., Jr. and Harris, R.T, Hypnotics - Methods of Development and Evaluation, New York: Spectrum Publications, Inc., 283-291, 1975.
33. SOMATIC AND PSYCHIATRIC BERAVIOR OF ALCOHOLISM. Fabre, L.F., Jr., Human Behavior and the Use and Abuse of Alcohol, W.L. Gideon, Ed, Continuing Education Center, University of Houston, Houston, Texas, 56-62, 1975.
34. DOUBLE-BLIND PLACEBO CONTROLLED EFFICACY STUDY OF KETAZOLAM (U-28,774). Fabre, L.F., Jr., Harris, R. T. and Stubbs D. F., The Journal of International Medicine, 4:50-54, 1976.
35. PREFERENCE STUDIES OF TRIAZOLAM WITH STANDARD HYPNOTICS IN OUT-PATIENTS WITH INSOMNIA Fabre, L.F., Jr., McLendon, D.M. and Harris, R.T., The Journal of International Medicine, 4:247-254, 1976.
36. PILOT OPEN-LABEL STUDY OF LENPERONE (AHR 2277), A BUTYROPHENONE IN ANXIETY. Fabre, L.F., Jr. and Harris, R.T., Current Therapeutic Research, 19(5):328-331, March, 1976.
37. PSYCHOLOGICAL PATTERNS IN PILOTS LEADING TO AIRCRAFT ACCIDENTS -MAN IS NOT A RATIONAL ANIMAL. Fabre, L.F., Jr., Aviation Medicine Bulletin, 1976.
38. PSYCHOLOGICAL PATTERNS IN PILOTS LEADING TO AIRCRAFT ACCIDENTS OMNIPOTENCE, PSYCHOSIS AND NEUROSIS IN PILOTS. Fabre, L.F., Jr., Aviation Medicine Bulletin, 1976.
39. PSYCHOLOGICAL PATTERNS IN PILOTS LEADING TO AIRCRAFT ACCIDENTS -THE PILOT WITH A PERSONALTY DISORDER. Fabre, L.F., Jr., Aviation Medicine Bulletin, 1976.
*40. PILOT OPEN-LABEL STUDY WITH ALPRAZOLAM (U-31, 889) IN OUT-PATIENTS WITH NEUROTIC DEPRESSION. Fabre, L.F., Jr., Current Therapeutic Research, 19(6):661-667, June, 1976.
*41. MULTI-CLINIC CROSS-OVER COMPARISON OF TRIAZOLAM AND PLACEBO IN THE TREATMENT OF CO-EXISTING INSOMNIA AND ANXIETY IN ANXIOUS OUT-PATIENTS. Fabre, L.F., Jr. and Smith, W.T., Diseases of the Nervous System, 38(6):487-491, June, 1977.
42. PILOT OPEN-LABEL STUDY OF ALPRAZOLAM (U-31, 889) IN ANXIOUS ALCOHOLIC OUT-PATIENTS. Fabre, L.F., Jr., Gainey, A and Kemple, S., The Journal of International Medicine, 5(1):26-32, 1977.
43. PILOT OPEN-LABEL STUDY OF TRIAZOLAM IN THE TREATMENT OF INSOMNIA FOLLOWING ALCOHOL WITHDRAWAL. Fabre, L.F., Jr., McLendon, D.M., Gainey, A. and Kemple, S., Journal of Studies on Alcohol, 38(11):2188-2192, November, 1977.
44, MULTI-CLINIC DOUBLE BLIND COMPARISON OF TRIAZOLAM (HALCION) AND PLACEBO ADMINISTERED FOR 14 CONSECUTIVE NIGHTS IN OUT-PATIENTS WITH INSOMNIA. Fabre, L.F., Jr., Brachfeld, J., Meyer, L.R., Slowe, I.A., Calvo, R. and Metzler, C., Journal of Clinical Psychiatry, 39(8):679-682, August, 1978.
45. MULTI-CLINIC DOUBLE-BLIND COMPARISON OF TRIAZOLAM AND FLURAZEPAM FOR SEVEN NIGHTS IN OUT-PATIENTS WITH INSOMNIA Fabre, L.F., Jr., Ludwig, G., Pasigajen, V. and Metzler, C., Journal of Clinical Pharmacology, 17(7):402-409, July, 1977.
46. DOUBLE-BLIND PLACEBO CONTROLLED COMPARISON OF AMOXAPINE AND IMIPRAMINE IN DEPRESSED OUT-PATIENTS. Fabre, L.F., Jr., McLendon, D.M. and Gainey, A., Current Therapeutic Research, 22(5):611-619, November, 1977.
47. A DOUBLE-BLIND CLINICAL TRIAL OF LENPERONE IN OUT-PATIENTS WITH ANXIETY. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 22(6):900-908, December, 1977.
48. PILOT OPEN-LABEL STUDY OF BROFOXINE IN ANXIETY. Fabre, L.F., Jr., McLendon, D.M., Reynolds, J.W. and Hornyak, E.P., Current Therapeutic Research, 23(1):105-110, January, 1978.
49. DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF BUPROPIN HYDROCHLORIDE (WELLBATRIN) IN THE TREATMENT OF DEPRESSED IN-PATIENTS. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 23(3):393-402, March, 1978.
50. COMPARISON OF TRIAZOLAM 0.25MG AND FLURAZEPAM 30MG IN THE TREATMENT OF INSOMNIA. Fabre, L.F., Jr. and Metzler, C.M., Clinical Therapeutics, 1:339-347, 1978.
*51. NABILONE, A CANNABINOID, IN THE TREATMENT OF ANXIETY: AN OPEN-LABEL AND DOUBLE-BLIND STIJDY. Fabre, L.F., Jr., McLendon, D.M and Stark, P., Current Therapeutic Research, 24(2):161-169, July, 1978.
52. A DOUBLE-BLIND COMPARISON OF CLORAZEPATE MONOPOTASSlUM (AZENE) WITH DIAZEPAM (VALIUM) IN THE.TREATMENT OF ANXIOUS OUTPATIENTS. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 26(6):1019-1026, December, 1979.
53. DOUBLE-BLIND COMPARISON OF KETAZOLAM ADMINISTERED ONCE A DAY WITH DIAZEPAM AND PLACEBO IN ANXIOUS OUT-PATIENTS. Fabre, L.F., Jr., McLendon, D.M. and Gainey, A., Current Therapeutic Research, 24(8):875-883, December, 1978.
54. A DOUBLE-BLIND COMPARISON OF PRAZEPAM WITH DIAZEPAM, CHLORAZEPATE DIPOTASSIUM AND PLACEBO IN ANXIOUS OUT-PATIENTS, Fabre, L.F., Jr., McLendon, D.M and Mallette, A., The Journal of International Medical Research, 7(2):147-151,1979.
55. TRAZODONE EFFICACY IN DEPRESSION: A DOUBLE-BLIND COMPARISON WITH IMIPRAMINE AND PLACEBO IN DAY.HOSPITAL TYPE PATIENTS. Fabre, L.F., Jr., McLendon, D.M. and Gainey, A., Current Therapeutic Research, 25(6):827-834, June, 1979.
56. A COMPARISON OF TREBENZOMINE WITH CHLORDIAZEPOXIDE AND PLACEBO IN THE TREATMENT OF ANXIOUS-DEPRESSED OUT-PATIENTS. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 25(2):311-319, February, 1979.
*57. PRAZEPAM EFFICACY IN ANXIETY: A DOUBLE-BLIND COMPARATIVE STUDY WITH DIAZEPAM CHLORAZEPATE DIPOTASSIUM AND PLACEBO. Fabre, L.F., Jr., McLendon, D.M. and Mallette, A., Current Therapeutic Research, 25(4):527-532, April, 1979.
*58. A DOUBLE-BLIND STIUDY COMPARING THE EFFICACY AND SAFETY OF ALPRAZOLAM WITH DIAZEPAM AND PLACEBO IN ANXIOUS OUTPATIENTS. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 25:519-526, 1979.
59. COMPARISON OF THE THERAPEUTIC EFFECT, TOLERANCE, AND SAFETY OF KETAZOLAM AND DIAZEPAM ADMINISTERED FOR SIX MONTHS TO OUT-PATIENTS WITH CHRONIC ANXIETY NEUROSIS. Fabre, L.F., Jr., McLendon, D.M. and Stephens, AG., The Journal of International Medical Research, 9(3): 191-198, 1981.
60. A DOUBLE BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF ALPRAZOLAM WITH IMIPRAMINE AND PLACEBO IN PRIMARY DEPRESSION. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 27(5):474-482, March, 1980.
61. KETAZOLAM ADMlNISTERED ONCE-A-DAY COMPARED TO CHLORAZEPATE T.I.D. AND PLACEBO IN A DOUBLE BLIND STUDY TO ANXIOUS OUT PATIENTS. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 25(6):710-720, June, 1979.
62. A DOUBLE-BLIND COMPARISON OF THE ANXIOLYTIC EFFICACY OF ALPRAZOLAM AND CHLORDIAZEPOXIDE HYDROCHLORIDE IN THE CHRONIC WITHDRAWAL PERIOD FROM ALCOHOL. Fabre, L.F., Jr. and McLendon, D.M., Current Therapeutic Research, 26(4):430-439, October, 1979.
63. A DOUBLE BLIND COMPARISON OF ALPRAZOLAM WITH CHLORDIAZEPOXIDE IN THE TREATMENT OF ALCOHOL WITHDRAWAL. McLendon, D.M. and Fabre, L.F., Jr., Current Therapeutic Research, 26:1019-1026, 1979.
64. A DOUBLE-BLIND COMPARISON OF THE EFFICACY OF ALPRAZOLAM, CHLORDIAZEPOXIDE HYDROCHLORIDE AND PLACEBO IN THE CHRONIC WITHDRAWAL PERIOD FROM ALCOHOL. McLendon, D.M. and Fabre, L.F., Jr., Current Therapeutic Research, 28(3):427-433, September, 1980.
65. AN OPEN DOSE-FINDING STUDY OF MELPERONE IN NONPSYCHIOTIC OUT-PATIENTS WITH ANXIETY. Fabre, L.F., Jr. and Napoliello, M.J., Current Therapeutic Research, 30(3):427-433, September, 1981.
66. THE EFFICACY AND SAFETY OF NABILONE (A SYNTHETIC CANNABINOID) IN THE TREATMENT OF ANXIETY. Fabre, L.F., Jr. and McLendon, D.M., The Journal of Clinical Pharmacology, 21:377S-382S, 1981.
67. LONG-TERM THERAPY FOR DEPRESSION WITH TRAZODONE. Fabre, L.F., Jr. and Feighner, J.P., The Journal of Clinical Psychiatry, 44(1): 17-21, January 1983.
68. PRAZEPAM EFFICACY IN ANXIETY: A DOUBLE-BLIND COMPARATIVE STUDY WITH DIAZEPAM, CHLORAZEPATE DIPOTASSIUM AND PLACEBO. Fabre, L.F., Jr., McLendon, D.M. and Mallette, A., Current Therapeutic Research, 25(4), April, 1979.
69. PHASE IV OUT-PATIENT COMPARISON STUDY OF PRAZEPAM AGAINST PLACEBO, DIAZEPAM AND CLORAZEPATE DIPOTASSIUM IN ANXIETY. Fabre, L.F., Jr., McLendon, D.M and Mallette, A., Current Therapeutic Researoh, 28(5):784-791, November, 1980.
70. EFFICACY AND SAFETY OF HALAZEPAM IN MODERATE TO SEVERE ANXIETY. Fabre L.F., Jr., Zisook, S. and Aden, G., Postgraduate Medicine, 49-57, 1981.
71. A MULTICENTER EVALUATION OF BUPROPION VERSUS PLACEBO IN HOSPITALIZED DEPRESSED PATIENTS. Fabre, L.F., Jr., Brodie, H.K., Garver, D. and Zung, WK, The Journal of Clinical Psychiatry, 44(5):88-94, May, 1983.
72. COMPARISON OF ALPRAZOLAM, IMIPRAMINE AND PLACEBO IN THE TREATMENT OF DEPRESSION. Feighner, J.P., Fabre, L.F., Jr., Aden, G.C., Rickels, K. and Smith, W. T., Journ. of Amer. Med. Assoc., 249: No. 22, 3057-3064, June 10, 1983.
73. THE EFFECT OF ALCOHOL ON ALDOSTERONE METABOLISM. Fabre, L.F. Jr., Symposium Endocrinological Aspects of Ethanol Tolerance and Dependence, Sponsored by NIAAA and Washington University, TJ. Cicero et al Eds., Government Printing Office in Press.
74. TOLERANCE TO REPEATED INTRAVENOUS DOSES OF RANITIDINE HCL AND CIMENTIDINE HCI IN NORMAL VOLUNTEERS. Cohen, A and Fabre, L.F., Jr., Current Therapeutic Research, 34(3):475-482, September, 1983.
75. DROWSINESS SEDATION LEVELS IN ANXIOUS NEUROTIC OUTPATIENTS. Fabre, L.F., Jr., Johnson, PA and Greenblatt, D.J., Psychopharmacology Bulletin, 20:No. 1, 128-136, 1984.
76. THE EFFECTS OF ANTACID AND PROPANTHELINE ON THE ABSORPTION OF ORAL RANITIDINE. Donn, K.H., Eshelman, F.N., Plachetka, J.R., Fabre, L.F., Jr. and Powell, J.R., Pharmacotherapy, 4(2):89•92, April, 1984.
77. EFFICACY OF FLUOXETINE IN OUTPATIENTS WITH MAJOR DEPRESSION. Fabre, L.F., Jr. and Crismon, L., Current Therapeutic Research, 37(1):115-123, January, 1985.
78. TREATMENT OF DEPRESSION IN OUTPATIENTS: A CONTROLLED COMPARISON OF THE ONSET OF ACTION OF AMOXAPINE AND MAPROTILINE. Fabre, L.F., Jr., The Journal of Clinical Psychiatry, 46:521-524, 1985.
79. TRATAMIENTO PROLONGADO DE LADEPRESION CON TRAZODONE, Louis F. Fabre, M.D., Ph.D. and John P. Feighner, CIPRYS Depression, Ano 4 -No.9, 1985.
80. DOUBLE•BLIND COMPARISON OF BUSPIRONE WITH DIAZEPAM IN ANXIOUS PATIENTS. Fabre, L.F., Current Therapeutic Research, 41(5):751-759, May, 1987.
81. A FIXED-DOSE CLINICAL TRIAL OF FLUOXETINE IN OUTPATIENTS WITH MAJOR DEPRESSION. Fabre, L.F., Jr. and Putman, H.P., III, The Journal of Clinical Psychiatry, 48(10):406-408, October, 1987.
82. AN ASCENDING SINGLE-DOSE TOLERANCE STUDY OF WY-45,030, A BICYCLIC ANTIDEPRESSANT, IN HEALTHY MEN. Fabre, L.F., Jr. and Putman, H.P., III, Current Therapeutic Research, 42(5):901•909, November, 1987.
83. DEPRESSIVE SYMPTOMS AND INTELLECTUAL FUNCTIONING IN ANXIETY PATIENTS TREATED WITH CLORAZEPATE. Fabre, L.F., Jr. and Putman, H.P., III, J. The Journal of Clinical Psychiatry, 49(5):189-192, May, 1988.
84. LA PRINCIPAL VENTAJA DE LA TRAZODONA RESPECTO A LOS ANTIDEPRESIVOS ANTERIORES ES SU SEGURIDAD. Fabre, L.F. Forum Farma, No. 6:12, October, 1988.
*85. THE KINETIC AND DYNAMIC CHARACTERISTICS OF BENZODIAZEPINES IN THE TREATMENT OF ANXIETY. Fabre, L.F. Psychiatry and Psychobiology, Vol. 3/No. Special B, 175S-182S, 1988.
*86. UNITED STATES EXPERIENCE AND PERSPECTIVES WITH TRAZODONE. Fabre, L.F. Clinical Neuropharmacology, Vol. 12, Suppl. 1, pp. S11-S17, 1989
87. DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED DOSE TRIAL OF MINAPRINE IN PATIENTS WITH MAJOR DEPRESSION. Amersterdam JD, Dunner DL, Fabre LF, Kiev A, Rush AJ and Goodman LI. Pharmacopsychiatry, Vol. 22:137-143, 1989.
88. ANXIETY ASSOCIATED WITH DEPRESSION. Rakel RE, Baughman OL, Fabre LF, Sheikh JI, Davidson J, Hirschfeld RA and Robinson DS. Topics in Psychiatry for the Primary Care Physician, Vol I, No.2, Fall 1989.
89. CHEMICAL DEPENDENCE AND ABUSE POTENTIAL OF ANXIOLYTIC DRUGS. Batki SL, Baughman III O, Borison R, Fabre L and Steinberg J. Topics in Psychiatry for the Primary Care Physician, Vol. 1, No.3, Winter 1990.
90. EFFECTIVE PATIENT COMMUNICATION IN THE MANAGEMENT OF ANXIETY. Batki SL, Baughman ill 0, Borison R, Fabre L and Steinberg J. Topics in Psychiatry for the Primary Care Physician, Vol. I, No.3, Winter 1990.
91. PHARMACOLOGY OF ANXIOLYTIC AGENTS. Batki SL, Baughman III, O, Borison R, Fabre L and Steinberg J. Topics in Psychiatry for the Primary Care Physician, Vol. I, No.3, Winter 1990.
92. SWITCHING FROM THERAPY WITH BENZODIAZEPINES. Batki SL, Baughman III O, Borison R, Fabre L and Steinberg J. Topics in Psychiatry for the Primary Care Physician, Vol. I, No. 3, Winter 1990.
93. ANXIETY: DRUG USE, ABUSE, DEPENDENCE AND ADDICTION. Batki SL, Baughman III O, Borison R, Fabre L and Steinberg J. Topics in Psychiatry for the Primary Care Physician, Vol. I, No.3, Winter 1990.
*94. EFFECTS OF TRAZODONE ON INSOMNIA AND DEPRESSION. Fabre LF. Insomnia and Depression, Monograph published by Bristol-Myers Squibb Company, May 1990.
*95. CLINICAL EFFECTS OF THE 5HT-IA PARTIAL AGONIST BUSPIRONE: A COMPOSITE ANALYSIS IN THE TREATMENT OF DEPRESSION. Robinson DS, Rickels K, Feighner J, Fabre L. Gammans RE, Shrotriya RC, Alms DR, Andary J, Messina M. The Jonrnal of Clinical Psychopharmacology, Vol. 10 (Suppl. 3), p.67S-76S, June 1990.
*96. GEPIRONE IN THE TREATMENT OF MAJOR DEPRESSION. Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME and Reich LA. The Journal of Clinical Psychopharmacology, Vol. 10 (Suppl. 3), p. 77S-85S, June 1990.
*97. LA BUSPIRONE DANS LE TRAITEMENT SYMPTOMATIQUE DU SEVRAGE ALCOOLIQUE AIGU. Fabre LF, Vettrnino JP and Stephens A and McLendon D. Synapse, No 64 Special, p. 32-37, May 1990.
*98. EFFICACY OF BUSPIRONE IN DEPRESSION WITH AND WITHOUT MELANCHOLIA. Fabre LF, Vettraino JP and Saucedo C. Drug Therapy, Suppl: 18-24, August, 1990.
99. BUSPIRONE IN THE MANAGEMENT OF MAJOR DEPRESSION DISORDER: A PLACEBO-CONTROLLED COMPARISON. Fabre, LF. The Journal of Clinical Psychiatry: 55-61, September 1990.
*100. TRAZODONE DOSING REGIMEN - EXPERIENCE WITH SINGLE DOSING ADMINISTRATION. Fabre LF. The Journal of Clinical Psychiatry 51(9 suppl.):23-26, September 1990.
*101. THE TREATMENT OF ANXIETY. Fabre, LF. Advances in Therapy, Volume 7 No. 6:334-343, November/December 1990.
*102. DOUBLE-BLIND, MULTICENTER COMPARISON OF SERTRALINE AND AMITRIPTYLINE IN ELDERLY DEPRESSED PATIENTS. Cohn CK, Shrivastava R, Mendels J, Cohn, JB Fabre LF, Claghom JL, Dessain EC, ItiI TM and Lautin A. The Journal of Clinical Psychiatry, 51:12(suppl B), December 1990.
*103. COMPARATIVE EFFICACY AND SAFETY OF NQRTRIPTYLINE AND FLUOXETINE IN THE TREATMENT OF MAJOR DEPRESSION: A CLINICAL STUDY. L Fabre, MB Scharf, and TM Itil. The Journal of Clinical Psychiatry, 526(6, suppl):62-67, June 1991.
*104. BUSPIRONE'S UTILITY IN DEPRESSION AND MELANCHOLIA. Fabre LF. The Wallingford CNS Academy – Proceedings Highlights 1990 Monograph, p 20. Bristol-Myers Squibb Company, 1991.
*105. 5-HT1A AGONISTS IN THE TREATMENT OF MAJOR DEPRESSION. Fabre LF. The Journal of Clinical Psychiatry, Advances in Psychiatric Treatment Monograph Series, Vol. 1(No. 1):25-28, 1991.
106. BUSPIRONE IN MANAGEMENT OF MAJOR DEPRESSION (ABSTRACT). Fabre LF. Psychiatry Digest, 6:30, 1991.
*107. COMPARATIVE EFFICACY AND SAFETY OF NORTRIPTYLINE AND FLUOXETINE IN THE TREATMENT OF MAJOR DEPRESSION: A CLINICAL STUDY (ABSTRACT). L Fabre, MB Scharf, and TM ltil. Digest of Neurology and Psychiatry, Series 59:261, November-December, 1991.
*108. SERTRALINE AND THE ELDERLY (ABSTRACT). Fabre LF. Biological Psychiatry, Volume 2, International Congress Series 968:866-867, 1991.
*109. VENLAFAXINE IN DEPRESSED OUTPATIENTS. Khan A, Fabre LF and Rudolph R Psychopharmacology Bulletin, Vol 27. No.2, 1991.
110. A COMPARISON OF PAROXETINE, IMIPRAMINE AND PLACEBO IN DEPRESSED OUTPATIENTS. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J and Shrivastava RK. The British Journal of Psychiatry, 159:394-398, 1991.
*111. A SIX-WEEK, DOUBLE-BLIND TRIAL OF PAROXETINE, IMIPRAMINE, AND PLACEBO IN DEPRESSED OUTPATIENTS. Fabre LF. The Journal of Clinical Psychiatry, 53(2 suppl):40-43, 1992.
*112. USE OF BUSPIRONE IN PATIENTS WITH GERNERALIZED ANXIETY DISORDER AND COEXISTING DPRESIVE SYMPTOMS: A META-ANALYSIS OF EIGHT RANDOMIZED, CONTROLLED STUDIES. Gammaus RE, Stringfellow JC, Hvizdos AJ, Seidehammel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, and Rickels K Neuropsychobiology, Vol. 25, May, 1992.
113. ICI, 204, 636, A NOVEL, ATYPICAL ANTIPSYCHOTIC EARLY INDICATION OF SAFETY AND EFFICACY IN PATIENTS WITH CHRONIC, SUBCHRONIC SCHIZOPHERNIA, Fabre, LF, et al. Clinical Therapeutics, Volume 17, Number 3, May-June Pg. 366-378, 1995.
114. SERTRALINE SAFETY AND EFFICACY IN MAJOR DEPRESSION – A DOUBLE-BLIND FIXED DOSE MULTISITE COMPAIRSON WITH PLACEBO. Fabre LF, Abuzzahab FS, Amin M, Claghornn JL, Mendlels J, Petrie WM, Dube’S and Small JG Journal of Biological Psychiatry, Vol. 38:592-602 November 1995.
115. COMPARISON OF FLUVOXAMINE AND FLUOXETINE IN THE TREATMENT OF MAJOR DEPRESSION. Fabre LF, Rapaport, M, Coccaro, E., Sheline, Y., Holland, P. Prese, T. Journal of Clinical Psychopharmacology (In Press)
116. FLUVOXAMINE VS. IMIPRAMINE AND PLACEBO: A DOUBLE BLIND COMPARISON IN DEPRESSED PATIENTS, Fabre, LF, Birkhimer, LJ, Zabony, BA, Wong, LF, Kapik, BM, Inernational Clinical Psychopharmacology Vol. 11. 119-127 (1996)
117. A PLACEBO CONTROLLED STUDY OF THE D/5-HT2A ANTAGONIST FANANSERIN IN THE TREATMENT OF SCHIZOPHRENIA, Fabre, LF, Truffinet P, Tamminga, C, Meltzer HY, Riveiere, ME and Papillon-Downey, C (in press)
118. A DOUBLE-BLIND COMPARISON OF CITALOPRAM AND PLACEBO IN DEPRESSED OUTPATIENTS, Fabre, LF, Mendels, J, and Kiev, Ari (in press)
119. A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RESPONSE TRIAL OF VENLAFAXINE HYDROCHLORIDE IN THE TREATMENT OF MAJOR DERESSION, Fabre, LF, Rudolph, RL, Feighner, J., Rickels, K., Entsuah, R, and Derivan, AT. Journal of Clinical Psychiatry 59.3 March, 1998
120. MULTIPLE-DOSE PHARMACOKINETICS OF QUETIAPINE IN MALE SCHIZOPHRENIC PATIENTS, Fabre, LF, Wong, J., Ewing, BJ, Thyrum, PT, Yeh, C., and Brook, SD (in press B Pharmaceutical Research)
121. GEPIRONE AND l-(2-PYRIMIDINYL) B PIPERAZINE IN VITRO: HUMAN CYTOCHROMES MEDIATING TRANSFORAMTION AND CYTOCHROME INHIBITORY EFFECTS, Fabre, LF., von Moltke, Lisa L., et al (in press)
122. DOUBLE-BLIND COMPARISON OF CITALOPRAM AND PLACEBO IN DEPRESSED OUTPATIENTS WITH MELANCHOLIA, Fabre, LF, Mendels, J, Kiev, A
123. A SENECCA ON A NIGHT FLIGHT ENCOUNTERS A METEOR, Fabre, LF, 1999
(*See Publications)
*1. EFFECT OF QUINONES ON ALDOSTERONE SECRETION. Farrell, G.L., Fabre, L.F., Jr. and McIsaac, W.M, Proc. 47th Annu. Mig. Endocr. Soc., 1964.
2. GAS-LIQUID CHROMATOGRAPHY WITH QUANTITATIVE ELECTRON CAPTURE ANALYSIS OF ALDOSTERONE AND CORTISOL FROM BLOOD. Fabre, L.F., Jr., Smith, R.E. and Farrell, G.L., Physiol., 10:164, 1967.
3. ALDOSTERONE SECRETION RATES IN FIVE DAY POSTOPERATIVE NEPHRECTOMIZED DOGS. Farrell, G.L. and Fabre, L.F., Jr., Physiol., 10:166, 1967.
4. BENZOQUINONE INHIBITION OF ADENAL STERIODOGENISIS. Fabre, L.F., Jr., Dissertation Abstracts, 27(10):365IVC, 1967.
*5. QUANTITATIVE ANALYSIS OF ALDOSTERONE AND CORTISOL FROM BLOOD BY GAS CHROMATOGRAPHY AND C TRACERS. Fabre, L.F., Jr. and Farrell, G.L., Proc. 12th Annu. Syrmp. in Adv. in Tracer Meth., 1967.
*6. ALDOSTERONE SECRETION IN RESPONSE TO HEMORRHAGE. Fabre, L.F., Jr., Turner, C., Smith, R. and Farrell, G.L., Excerpta Medica, 157:206, 1968.
*7. ISOLATION OF 7-DEHYDROCHOLESTEROL AND VITAMIN D FROM HUMAN SKIN. Rauschkolb, E.W. and Fabre, L.F., Jr., Proc. 29th Mtg. Soc. for Invest. Derm., 2:24, 1968.
*8. DETERMINATION OF ALDOSTERONE AND TETRAHYDROALDOSTERONE IN BLOOD BY ELECTRON CAPTURE GAS CHROMATOGRAPHY. Fabre, L.F., Jr., Fenimore, D.C., Farmer, R.W., Davis, H.W. and Farrell, G.L., 5th Inter. Symp. in Adv. in Chrom., 1969.
9. ETHANOL INHIBITION OF THE ALDOSTERONE RESPONSE TO HEMORRHAGE. Fabre, L.F., Jr., Farmer, R.W. Davis, H.W.; Cross, J. and Farrell, G.L., FAS.E.B., 38:635, 1969.
10. INSTABILITY OF MEMBRANE POTENTIAL IN AN EPILEPTIC PATIENT. Roger, G., Fabre, L.F., Jr., and Farrell, G.L., (Sponsored by A.C. Griffin), F.A.S.E.B., 28:892, 1969.
11. EFFECTS OF ETHANOL ON ALDOSTERONE SECRETION. Fabre, L.P., Jr., Farrell, G.L., Davis, H.W. and Farmer, R.W., Proc. 51st Mtg. Endocr. Soc., 6:141, 1969.
12. ABOLITION OF GROWTH HORMONE ADIPOKINESIS BY PANCREATECTOMY. Farmer, R.W., Loeffel, E.D., Ismail, K.V. and Fabre, L.F., Jr. (Introduced by E.W. Rauschkolb), 51st Mtg. Endocr. Soc., 6:141, 1969.
*13. EFFECT OF ETHANOL ON ADRENOCORTICAL STERIOD SECRETION. Fabre, L.F., Jr., Farmer, R. W. and Davis, H.W., Proc. 3rd Annu. Symp. Biol. Aspects of Alc., Houston, Texas, 1969.
*14. IMMUNOASSAY OF ALDOSTERONE. Farmer, R.W., Roup, W.G., Jr., Farrell, G.L. and Fabre, L.F., Jr., FAS.E.B. 2:828 Abs. (3315), 1970.
*15. COMPUTER ASSISTED COLUMN CALIBRATION FOR GAS-LIQUID CHROMATOGRAPHY OF BIOLOGICAL COMPOUNDS. Talbot, P., Pellizzari, E.D., Brown, J.H., Farmer, R.W. and Fabre, L.F., Jr., Proc. 6th Annu. Mtg. Chrom., 6:86, 1970.
16. GAS-LIQUID CHROMATOGRAPHY AMINO ACID ANALYSIS OF NORMAL AND ABNORMAL HAIR. Brown, J.H., Pellizzari, E.D., Fabre, L.F., Jr. and Rauschkolb, E.W., Proc. 31st Mtg. Soc. Invest. Derm., 6:12(5), 1970.
*17. HYPERLYSINURIA WITH HYPERAMMONEMIA Brown, J.H., Fabre, L.F., Jr., Farrell, G.L. and Adams, E.D., Clin. Rsch., 2:452, 1970.
18. GAS CHROMATOGRAPHIC ANALYSIS OF AMINO ACIDS IN HUMAN PLASMA Pellizzari, E.D., Brown, J.H., Farmer, R W., Talbot, P.L. and Fabre, L.F., Jr., Clin. Rsch., 2:462, 1970.
19. THE EFFECTS OF ETHANOL ON HUMAN URINARY ALDOSTERONE EXCRETION. Fabre, L.F., Jr., Farmer, R W., Pellizzari, E.D. and Farrell, G.L., Clin. Rsch., 2:359, 1970.
*20. RADIOIMMUNOASSAY OF ALDOSTERONE. Farmer, R W., Roup, W.G., Jr., Pellizzari, E.D. and Fabre, L.F., Jr., Proc. 52nd Mtg. Endocr. Soc., 145:109, 1970.
*21. ADRENAL RESPONSE TO ALCOHOL: MINERALOCORTICOID METABOLISM Fabre, L.F., Jr., Farmer, R W., Pellizzari, E.D. and Mendelson, J.H., Conf. Recent Adv. In Alcoholism, (by invitation), Washington, D.C., 1970.
*22. GROWTH HORMONE DOES NOT CAUSE GLUCAGON SECRETION. Farmer, R W., Fabre, L.F., Jr., Sugase, T., Nonaka, K and Foa, P.P., (introduced by RA Higgins), Proc. AP.S. 21st Mtg., 1970.
23. THE EFFECT OF ETHANOL ON ALDOSTERONE SECRETION IN MAN. Fabre, L.F., Jr., Farmer, R W., Pellizzari, RD. and Farrell, G.L., Proc. AP.S. 21st Mtg., 129:26, 1970.
*24. PLASMA AMINO ACID ANALYSIS BY GAS-LIQUID CHROMATOGRAPHY. Pellizzari, E.D., Brown, J.H., Farmer, R W. and Fabre, L.F., Jr., Proc. AC.S. Reg. Mtg., 111:34, 1970.
25. SERUM INSULIN LEVELS DURING ORAL GLUCOSE TOLERANCE TEST IN CHRONIC ALCOHOLICS. Farmer, R W., Farrell, G.L., Pellizzari; RD. and Fabre, L.F., Jr., Proc. F.AS.E.B. 55th Annu. Mtg., 35:350 Abs., 1971.
26. PERIPHERAL SERUM BILE ACID LEVELS IN NORMAL AND ALCOHOLIC SUBJECTS. Fabre, L.F., Jr., Medlin, J., O'Neil, F.S. and Pellizzari, E.D., Tex. Med., 67:6, 1971.
*27. METABOLIC DISEASE IN MENTAL RETARDATION –A STUDY IN TEXAS. Farrell, G.L., Johnson, R, Fabre, L.F., Jr., Farmer, R W., Pellizzari, RD. and Stephenson, M, 3rd Conf. Clinic. Delineation of Birth Def.,John Hopkins Hospital, Baltimore; MD, 1971.
28. THE EFFECTS OF CHLESTYRAMINE UPON SERUM BILE ACIDS IN HEALTHY VOLUNTEERS. O'Neil, F.S., Fabre, L.F., Jr., Pe11izzari, E.D., Medlin, J and Kelsey, J.R, Gastroentrology, 60(4):702, 1971.
*29. A RAPID RADIOMMUNOASSAY (RIA) FOR ALDOSTERONE. Farmer, R W., Roup, W.G., Jr., Pel1izzari, E.D. and Fabre, L.F., Jr., Proc. 53rd Annu. Mtg. Endocr. Soc., 101:A-93, 1971.
30. ABOLITION OF GROWTH HORMONE LIPOLYSIS BY HEXAMTHONIUM GANGLIONIC BLOKCADE. Farmer, R.W. Pellizzari, E.D. and Fabre, L.F., Jr., Proc. AP.S. 22nd Annu. Mtg., 1971.
*31. ABNORMAL TESTOSTERONE EXCRETION IN MALE ALCOHOLICS. Fabre, L.F., Jr., Pellizzari, E.D., Pasco, P.J. and Farmer, R W., 22nd Autumn Mtg. AP.S., 1971.
*32. ABNORMAL TESTOSTERONE EXCRETION IN MALE ALCOHOLICS. Fabre, L.F., Jr., Pe11izzari, E.D. and Farmer, R W., 5th World Cong. of Psychia, 1971.
*33. FAILURE OF GROWTH HORMONE TO STIMULATE GLUCAGON SECRETION. Farmer, R W., Pe11izzari, E.D., Fabre, L.F., Jr., Nonaka, K., Sugase, T. and Foa, P.P., P.S.E.B.M., 138(2):491, 1971.
34. SYNTHESIS OF 3-(0-CARBOXMETHYLENE) OXIMINO-11 BETA, 18-EPOSYANDROST-4-ENE-17 BETA, 18 CARBOLACTONE (AGLO) AS A HAPTENIC ANTIGEN, Cross, J.H., Pellizzari; E.D., Fabre, L.F., Jr. and Farmer, R.W., Reg. Mtg. A.C.S., 1971.
*35. CORTICOSTERIOD METABOLISM IN CHRONIC ALCOHOLICS. Fabre, L.F., Jr., Pellizzari, E.D., Farmer, R.W., Fleischer, N.S., Mello, MK., Wolin, A. and Mendelson, J.H., Jr., Fall Met. A.S.P.E.T. and D.M.CAC.S. Pharmacol., 13:2, 1971.
36. ENDOCRINE ABNORMALITIES IN MALE ALCOHOLICS. Fabre, L.F., Jr., Brown, J.H., Howard, P.Y. and Farmer, R.W., T.M.A Annu. Session, May 11-14, 1972.
37. PERIPHERAL SERUM BILE ACID LEVELS IN RESPONSE TO ORAL FEEDINGS. Fabre, L.F., Jr., O’Neil, F.S., Farmer, R W., Howard, P.Y. and Brown, J.H., T.M.A. Annu. Session, May 11-14, 1972.
38. RENAL TRANSPORT OF BASIC AMINO ACIDS. Brown, J.H., Farrell, G.L. and Fabre, L.F., Jr., Clin. Res., 1971.
*39. LACK OF EFFECT OF GROWTH HORMONE ON PLASMA FREE FATTY ACIDS AFTER SPINAL CORD SECTION, Farmer, R.W., Howard, P.Y. and Fabre, L.F., Jr., Clin, Res., 20(3), 1972.
40. BIOCHEMICAL AND METABOLIC ASPECTS OF ALCOHOLISM. Fabre, L.F., Jr., Farmer, R.W., Roach, M.K., Fritchie, G.E. and McIssac, W.M., Nat’l. Council on Alcoholism Annu. Mtg., April 11-12 1972.
*41. ABNORMAL ANDROGEN METABOLISM IN MALE ALCOHOLIC SUBJECTS. Fabre, L.F., Jr. Brown, J.H. Howard, P.Y. and Farmer, R.W., 5th Int’l Congress Pharm., 1972.
42. ANDROGEN METABOLISM IN ALCOHOLICS. Fabre, L.F., Jr. (presented by P.Y. Howard), T.M.A. Annu. Session, May 11-12, 1972.
43. PLASMA TESTOSTERONE AND SIX HORMONE BINDING GLOBULIN (SGB) IN ALCOHOLIC SUBJECTS. Liegel, J., Fabre, L.F., Jr., Howard, P.Y. and Farmer, R.W., Physiol., 15(3):198, 1972.
*44. RADIOIMMUNOASSAY (RIA) OF ALDOSTERONE WITHOUT CROMOTOGRAPHY. Farmer, R.W., Brown, D.H., Howard, P.Y. and Fabre, L.F., Jr., Clin. Rsch., 1972.
*45. RADIOIMMUNOSSAY (RIA) OF PLASMA ALDOSTERONE WITH NO CHROMOTOGRAPHY. Farmer, R.W., Brown, D.H. and Fabre, L.F., Jr., 57th Annu. Mtg., F.A.S.E.B., April 15-20, 1973.
46. EVIDENCE FOR THE FEEDBACK OF DEHYDROEPIANDROSTERONE (DHA) UPON THE PINEAL IN MICE. Farmer, R.W. and Fabre, L.F., Jr., Clin. Rsch., XXII(2):236A, 1974.
47. ACUTE EFFECTS OF ETHANOL ON PLASMA ALDOSTERONE, CORTASOL AND RENIN IN NORMAL YOUNG MEN. Farmer, R.W. and Fabre, L.F., Jr., Intern’l Rsch. Comm. Syst., 1974.
48. AN ANALYSIS OF CLINICAL FACTORS IN THE ABUSE POTENTIAL OF NEW ANTI-ANXIETY AND ANTI-DEPRESSANT DRUGS. Fabre, L.F., Jr. and Harris, R.T., Brooklodge Conf. in Hypnotics, Sponsored by Up-John Co., Kalamazoo, Michigan, July 24-26, 1974.
*49. BIOCHEMICAL AND METABOLIC ASPECTS OF ALCOHOLISM. Fabre, L.F., Jr., Farmer, R.W., Roach, M.K., Fritchie, G.E. and McIssac, W.M., Abs. Series, Inst. for Documentation and Information on Sozialmedizin and Offentliches Gesundheitswesen, Bielelfeld, West Germany, 1974.
50. PSYCHOLOGICAL PATTERNS IN PILOTS LEADING TO AIRCARFT ACCIDENTS. Fabre, L.F., Jr., Texas Medical Association 108th Annual Session, San Antonio, Texas, May 1-4, 1975.
51. PSYCHOLOGICAL PATTERNS IN PILOTS LEADING TO AIRCRAFT ACCIDENTS, Fabre, L.F., Jr., Intern’l. Cong. of Aviation and Space Med., Acapulco, Mexico, September 29-October 2, 1975.
52. NURSING ASSISTANCE IN PSYCHOPHARMACOTHERAPY. Fabre, L.F., Jr. and Gainey, A., VI World Congress of Social Psychiatry, Opatija, Yugoslavia, October 4-10, 1976.
*53. A DOUBLE BLIND CLINICAL TRIAL OF WELLBATRIN -A NOVEL ANTIDEPRESSANT. Fabre, L.F., Jr., McLendon, D.M and Mallette, A., Seventy-Eighth Annu. Mtg. of the American Soc. for Clinical Pharm. and Thera., March, 1977.
*54. DOUBLE BLIND CLINICAL TRIAL OF AMOXAPINE COMPARED WITH IMIPRAMINE AND PLACEBO IN OUT-PATIENTS WITH DEPRESSIVE ILLNESS. Fabre, L.F., Jr., VI World Cong. of Psychiatry, Honolulu, Hawaii, September, 1977.
*55. A DOUBLE BLIND CLINICAL TRIAL OF LENPERONE IN OUT-PATIENTS WITH ANXIETY. Fabre, L.F., Jr., Dent, W. and Cummings, W., VI World Cong. of Psychiatry, Honolulu, Hawaii, September, 1977.
*56. DOUBLE BLIND STUDY OF KETAZOLAM, DIAZEPAM AND PLACEBO IN ANXIOUS OUT-PATIENTS. Fabre, L.F., Jr., McLendon, D.M. and Gainey, A, ASCPT 79th Annu. Mtg., Atlanta, Georgia, March 29-31, 1978.
*57. PRAZEPAM EFFICACY IN ANXIETY. Fabre, L.F., Jr., Mallette, A., McLendon, D.M. and Rickels, K.., 11th C.I.N.P. Cong. Collegium Int'l. Neuro-Psychopharmacologium, Vienna, Austria, July 9-14, 1978.
*58. COMPARISON OF TRIAZOLAM AND PLACEBO IN THE TREATMENT OF INSOMNIA AND ANXIETY IN OUT-PATIENTS WITH ANXIETY NEUROSIS. Fabre, L.F., Jr., McLendon, D.M. and Purpura, R, American College of Clinical Pharmacology, San Francisco, California, April 26-29, 1978.
*59. DOUBLE BLIND TRIAL OF AMOXAPINE COMPARED WITH IMIPRAMINE AND PLACEBO IN OUT-PATIENTS WITH DEPRESSIVE ILLNESS. Fabre, L.F., Jr., Psychiatry Digest, January, 1978.
*60. DOUBLE BLIND CLINICAL TRIAL OF WELLBATRIN -A NOVEL ANTIDEPRESSANT. Fabre, L.F., Jr., McLendon, D.M and Mallette, A., Psychiatry Digest, May, 1978.
*61. CLINICAL AND PRECLINICAL PHARMACOLOGY OF A SYNTHETIC CANNABINOID, NABILONE (LILLY COMPOUND 109514). Stark, P., Fabre, L.F., Jr., Newell, F.W and Einhorn, L., 11th Cong. Collegium Int'1. Neuro-Psychopharmacologiurm, Vienna, Austria, July 9-14, 1978.
*62. COMPARISON OF TRIAZOLAM 0.25MG. AND FLURAZEPAM #1.0MG. IN THE TREATMENT OF INSOMNIA. Fabre, L.F., Jr., McLendon, D.M. and Metzler, C., 7th Int'1. Cong. of Pharm., Paris, France, July 16-21, 1978.
63. OPEN LABEL IN-PATIENT EVALUATION OF A NEW ANXIOLYTIC-FENOBAM Fabre, L.F., Jr. and McLendon, D.M, Clinical Rsch., 25(3).
64. WHAT IS ANXIETY? Schmatolla, E., McLendon, D.M and Fabre, L.F., Jr., 7th Int'1. Cong. of Social Psychiatry, Lisbon, Portugal, October 8-14, 1978.
65. SOCIAL ASPECTS OF ANXIETY. Fabre, B.M., Gainey, A. and Fabre, L.F., Jr., 7th Int'l. Cong. of Social Psychiatry, Lisbon, Portugal, October 8-14, 1978.
66. PHARMACOTHERAPY OF ANXIETY. Fabre, L.F., Jr. and McLendon, D.M., 7th Int'l. Congo of Social Psychiatry, Lisbon, Portugal, October 8-14, 1978.
67. MIXED ANXIETY-DEPRESSION. Fabre, L.F., Jr., 7th Int'l. Congo of Soc. Psychiatry, Lisbon, Portugal, October 8-14, 1978.
68. ALPRAZOLAM EFFICACY IN ANXIETY. Fabre, L.F., Jr., ASCPT 80th Annual Meeting, Kansas City, Missouri, March 21-23, 1979.
*69. A DOUBLE BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF ALPRAZOLAM WITH IMIPRAMINE AND PLACEBO IN PRIMARY DEPRESSION. Fabre, L.F., Jr., American College of Clin. Pharm., Washington, D.C., May 3-4, 1979.
*70. COMPARISON OF THE THERAPEUTIC EFFECT, TOLERANCE AND SAFETY OF KETAZOLAM AND DIAZEPAM ADMINISTERED FOR SIX MONTHS TO OUT-PATIENTS WITH CHRONIC ANXIETY NEUROSIS. Fabre, L.F., Jr., American College of Clin. Pharm., Washington, D.C., May 14-16, 1980.
*71. PRAZEPAM EFFICACY IN ANXIETY. Fabre, L.F., Jr., 12th Cong. Collegium Int'l. Neuropsychopnarmacologium, Gothenburg, Sweden, June 22-26, 1980.
72. VALIUM AND AZENE EFFICACY AND PLASMA LEVELS IN ANXIETY. Fabre, L.F., Jr., McLendon, D.M. and Greenblatt, D., 1st World Conf. on Clin. Pharm. and Ther., London, England, July 6-9, 1980.
*73. THE EFFICACY AND SAFETY OF CANNABINOID NABILONGE (A SYNTETIC CANNABINOID) IN THE TREATMENT OF ANXIETY. Fabre, L.F., Jr., Ther. Progress in Cannabinoid Rsch., A symposium sponsored by Pfizer, Groton, Connecticut, October 20-21, 1980.
*74. A MULTI-CENTER EVALUATION OF BUPROPION VERSUS PLACEBO IN HOSPITALIZED DEPRESSED PATIENTS. Fabre, L.F., Jr., Brodie, H.K.H., Garver, D. and Zung, W.W.K., An Approach to Dilemmas in the Pharmacotherapy of Depression: A New Generation Antidepressant. Symposium sponsored by Duke University medical Center, Orlando, Florida, February 4-5, 1982.
75. AN OPEN TRIAL OF LOFEXIDINE IN PATIENTS WITH SYMPTOMS OF ALCOHOL WITHDRAWAL. Fabre, L.F., Jr., Reed, N. and Cawein, M., Clin. Res., 1983.
76. THE EFFECT OF ALCOHOL ON ALDOSTERONE SECRETION AND METABOLISM. Fabre, L.F., Jr., Symposium Endocrinological Aspects of Ethanol Tolerance and Dependence, sponsored by NIAAA and Washington University, Kansas City, Missouri, September 13, 1982.
77. CURRENT RESEARCH: ANTIANXIETY AGENTS. Louis F. Fabre, MD. Ph.D., Psychiatric Perspectives "83", sponsored by Orlando Regional Medical Center and the University of Florida, March 11-12, 1983.
78. CURRENT RESEARCH: NEW ANTIDEPRESSANT AGENTS. Louis F. Fabre, M.D., Ph.D., Psychiatric Perspectives "83", sponsored by Orlando Regional Medical Center and the University of Florida, March 11-12, 1983.
79. DROWSINESS-SEDATION LEVELS IN ANXIOUS NEUROTIC OUTPATIENTS. NCDEU Annnal Meeting, sponsored by the National Institute of Mental Health, May 30 -June 2, 1983.
*80. DROWSINESS-SEDATION LEVELS IN ANXIOUS NEUROTIC OUTPATIENTS. Fabre, L.F., Jr., Johnson, P.A. and Greenblatt, D.J., II World Conference on Clinical Pharmacology & Therapeutics, Washington, D.C., August 3, 1983.
81. A COMPARISON OF THREE-TIMES DAILY AND SINGLE NIGHTTIME DOSAGE OF PRAZEPAM IN ANXIOUS NEUROTIC OUTPATIENTS. Fabre, L.F., Jr., Johnson, P.A. and Greenblatt, D.J., American Academy of Family Physicians, Miami, Florida, October 10, 1983.
82. TRAZODONE TREATMENT OF CHRONIC DEPRESSION. Louis F. Fabre, Jr., M.D., Ph.D., Asociacion Argentina De Psiquiatria Biologica, Buenos Aires, Argentina, September 2, 1985.
83. ANXIETY: DIAGNOSIS AND CURRENT TREATMENT PERSPECTIVES. Lonis F. Fabre, MD., Ph. D., Texas Academy of Physician Assistants, Corpus Christi, Texas, September 14, 1985..
*84. THE KINETIC AND DYNAMIC CHARACTERISTICS OF BENZODIAZEPINES IN THE TREATMENT OF ANXIETY. Louis F. Fabre, M.D., Ph.D., Clinical and Cognitive Aspects of Anxiety. a symposium sponsored by Laboratories Substantia and Warner-Lambert Company, Paris, France, January 28, 1988.
85. DIFFERENTIAL DIAGNOSIS AND CURRENT TREATMENT OF ANXIETY. Louis F. Fabre, M.D., Ph.D. Buspirone Symposium sponsored by Bristol-Myers Company and Boryung Pharmaceuticals. Seoul Korea, June 24, 1988 and Pusan Korea, June 25, 1988.
*86. A STUDY OF PAROXETINE, IMIPRAMINE, AND PLACEBO IN THE TREATMENT OF DEPRESSED OUTPATIENTS. Louis F. Fabre, M.D., Ph.D. XVIth Collegium Internationale Neuro-Psychopharmacologicum Congress. Munich, West Germany, August 15-19, 1988.
*87. UNITED STATES EXPERIENCE AND PERSPECTIVES WITH TRAZODONE. Louis F. Fabre, M.D., Ph.D. Symposium on "Trazodone An Antidepressant With Adrenolytic Activity" sponsored by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A Munich, West Germany, August 15, 1988.
*88. TRAZODONE DOSING REGIMEN -EXPERIENCE WITH SINGLE DOSING ADMINISTRATION. Louis F. Fabre, M.D., Ph.D. Symposium on "Insights in the Use of Trazodone in Depressed Patients". VIIIth World Congress of Psychiatry. Athens Greece, October 12-19, 1989.
*89. BUSPIRONE IN THE SYMPTOMATIC TREATMENT OF ACUTE ALCOHOL WITHDRAWAL (ABSTRACT). Louis F. Fabre, M.D., Ph.D., Julie Powers Vettraino, RN, MSN, Allison Stephens, RN and David McLendon, Ph.D. VIIIth World Congress of Psychiatry. Athens Greece, October 12-19, 1989.
90. SERTRALINE TREATMENT OF GERIATRIC MAJOR DEPRESSION COMPARED WITH AMITRIPTYLINE. Louis F. Fabre, M.D., Ph.D. Symposium on "Serotonin Reuptake Inhibition in the Management of Depression". 'VIIIth World Congress of Psychiatry. Athens Greece, October 12-19, 1989.
*91. DOUBLE-BLIND, MULTICENTER COMPARISON OF SERTRALINE AND AMITRIPTYLINE IN ELDERLY DEPRESSED PATIENTS. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM and Lautin A. Symposium on "Serotonin Reuptake Inhibition in the Mangement of Depression". VIIIth World Congress of Psychiatry. Athens Greece, October 12-19, 1989.
*92. THE TREATMENT OF ANXIETY. Louis F. Fabre, M.D., Ph.D. Symposium on "New Horizons in Anxiety Therapy", sponsored by Science & Medicine Canada. Vancouver, British Columbia, November 18, 1989.
*93. GEPIRONE IN THE TREATMENT OF MAJOR DEPRESSION. Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME and Reich LA American College of Neuropsychopharmacology (ACNP) 1989 Annnal Meeting. Maui, Hawaii, December 10-15, 1989.
*94. USE OF BUSPIRONE IN DEPRESSION WITH AND WITHOUT MELANCHOLIA (ABSTRACT). Louis F. Fabre, M.D., Ph.D. Symposium, Mead Johnson Pharmaceuticals’ Visiting Faculty Program Meeting. Scottsdale, Arizona, March 9-10, 1990.
*95. BUSPIRONE'S UTILITY IN DEPRESSION AND MELANCHOLIA. Louis F. Fabre, M.D., Ph.D., "The Wallingford CNS Academy" meeting, Bristol-Myers Squibb Company. New York, New York, May 11, 1990.
*96. COMBINED BUSPIRONE -FLUOXETINE IN SEVERE DEPRESSION (ABSTRACT). Louis F. Fabre, M.D., Ph.D., Julie Powers Vettraino, RN, MSN and Cynthia Saucedo, M.D. American Psychiatric. Association 143rd Annnal Meeting. New York, New York, May 12-17,1990.
97. A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CITALOPRAM IN MAJOR DEPRESSIVE DISORDER (ABSTRACT). Joseph Mendels, Louis Fabre, and Ari Kiev. NCDEU 30th Annnal Meeting. Key Biscayne, Florida, May 29-June 1, 1990.
*98. VENLAFAXINE IN DEPRESSED OUTPATIENTS (ABSTRACT). Arif Khan, Louis Fabre, Stephen Dager and David Dunner. NCDEU 30th Annual Meeting. Key Biscayne, Florida, May 29-June 1, 1990.
99. DEPRESSION IN THE ELDERLY. Louis F. Fabre, M.D., Ph.D. Scientific Session, Recent Advances in Psychopharmacology. Ontario Medical Association 110th Annual Meeting, sponsored by Pfizer Canada Inc. Toronto, Ontario Canada, June 4-8, 1990.
100. ICI 204,636, A NOVEL ATYPICAL ANTIPSYCHOTIC: EARLY INDICATION FOR SAFETY AND EFFICACY IN MAN (ABSTRACT). L. Fabre, V. Slotnick, V. Jones, G. Murray and J. Malick. 17th Collegium Internationale Neuro-Psychopharma-cologicum Congress. Kyoto, Japan, September 10-14, 1990.
*101. 5HT1A AGONISTS IN THE TREATMENT OF MAJOR DEPRESSION (ABSTRACT). Louis Fabre. "Serotonin and Depression: Neuropharmacology and New Dimensions in Treatment" Satellite Symposium, Bristol-Myers Squibb Company. Kyoto, Japan, September 13, 1990.
*102. COMPARATIVE EFFICACY AND SAFETY OF NORTRIPTYLINE AND FLUOXETINE IN THE TREATMENT OF MAJOR DEPRESSION: A CLINICAL STUDY. LF Fabre, MB Scharf, and TM Itil. "The Clinician's Challenge: Strategies for Treatment of Depression in the 1990's" Symposium, sponsored by Sandoz Pharmaceuticals Corporation. Phoenix, Arizona, February 15, 1991.
103. THE DIAGNOSIS AND TREATMENT OF ANXIETY AND RELATED DISORDERS. Louis Fabre. Symposium sponsored by Bristol-Myers Squibb (Pty) Limited South Africa. Eastern Transvaal, South Africa, February 22-23, 1991.
104. THE PSYCHOPHARMACOLOGIC TREATMENT OF DEPRESSION. Louis Fabre. Symposium sponsored by Bristol-Myers Squibb (Pty) Limited South Africa. Eastern Transvaal, South Africa, February 22-23, 1991.
105. ZALOSPIRONE: A NEW SEROTONIN-1A PARTIAL ANTAGONIST - PHASE 1 STUDIES (ABSTRACT). LF Fabre, S Troy, and AT Derivan. NCDEU 31st Annnal Meeting. Key Biscayne, Florida, May 28-31,1991.
*106. SERTRALINE AND THE ELDERLY (ABSTRACT). Louis Fabre. "Serotonin and Psychiatry: The Role of Sertraline" Satellite Symposium, Pfizer International. Florence, Italy, June 9, 1991.
*107. A DOUBLE-BLIND MULTICENTER STUDY COMPARING THE SAFETY AND EFFICACY OF SERTRALINE WITH PLACEBO IN MAJOR DEPRESSION (ABSTRACT). Louis F. Fabre. 5th World Congress of Biological Psychiatry. Florence, Italy, June 10-14, 1991.
108. BUSPIRONE IN THE TREATMENT OF MIXED ANXIETY-DEPRESSION. Symposium "New Trends in the Treatment of Anxiety," Louis F. Fabre, M.D., Ph.D. Sponsored by Bristol-Myers Squibb of Portugal. Oporto and Lisbon, Portugal, November 22-23, 1991.
109. THE TREATMENT OF ANXIETY, DEPRESSION AND RELATED DlSORDERS WITH SPECIAL REFERENCE TO THE EFFICACY OF BUSPIRONE. Louis F. Fabre, MD., Ph.D. Symposium sponsored by Bristol-Myers Squibb. Abu Dhabi, Dubai, and Al Ain, United Arab Emirates, December 15-17, 1991.
*110. AUGMENTATION OF ANTIDEPRESSANT RESPONSE AND IMPLICATIONS FOR COMBINATION THERAPY. Louis F. Fabre, M.D., Ph.D. Symposium, Mead Johnson Pharmaceuticals' Visiting Faculty Program Meeting. Tuscon, Arizona, Februaty 20-23, 1992.
111. EFFICACY AND SAFETY OF BID DOSES OF VENLAFAXINE IN A DOSE-RESPONSE STUDY (ABSTRACT). J Mendels, R Johnson, J Mattes, R Riesenberg, L Fabre, et aI. NCDEU 32nd Annual Meeting. Boca Raton, Florida, May 26-29, 1992.
112. ASCENDING SINGLE-DOSE SAFETY AND TOLERANCE OF WY-47,791 HCL, A NOVEL POTENTIAL ANTIPSYCHOTIC (ABSTRACT). L Fabre, S Leventer, L Goodman, M Welch, A Baker, and A Derivan. XVIII Collegium Internationale Neuro-Psychopharmacologicum Congress. Nice, France. June 28-July 2, 1992.
113. FLUVOXAMINE IN THE TREATMENT OF DEPRESSION. A DOUBLE-BLIND COMPARISON WITH IMIPRAMINE AND PLACEBO IN OUTPATIENTS WITH MAJOR DEPRESSION (ABSTRACT). L Fabre, J Vettraino, L Birkhimer, and V Houser. XVIII Collegium Internationale Neuro-Psychopharmacologicum Congress. Nice, France, June 28-July 2, 1992.
*114. COMPOSITE EVALUATION OF PLACEBO CONTROLLED STUDIES IN PATIENTS WITH GENERALIZED ANXIETY DISORDERS (DSM III) AND COEXISTING DEPRESSIVE SYMPTOMS. RE Gammans, AJ Hvizdos, RJ Seidehamel, JB Cohn, CS Wilcox, LF Fabre, JC Peckhold, WT Smith, and K Rickels. XVIII Collegium Internationale Neuro-Psychopharmacologicum Congress. Nice, France, June 28-July 2, 1992.
115. A MULTICENTER, OPEN PILOT TRIAL OF ICI 204,636 IN HOSPITALIZED PATIENTS WITH ACUTE PSYCHOTIC SYMPTOMATOLOGY (ABSTRACT). LF Fabre and L Arvanitis. International Congress on Schizophrenia Research. Colorado Springs, Colorado, April 17-21, 1993.
116. A DOUBLE-BLIND MULTICENTER TRIAL OF A LOW DOSE RANGE AND A HIGH DOSE RANGE OF GEPIRONE-ER COMPARED TO PLACEBO IN THE TREATMENT OF DEPRESSED OUTPATIENTS. (ABSTRACT) LF Fabre, C WiIcox, J Dale, J Ferguson, & J Cohn. NCDEU 35lh Aunnal Meeting, Orlando, Florida, May 31-June 3, 1995. Psychopharmacology Bulletin, 1995, Vol. 31, No.3, Page. 631
117. MULTIPLE DOSE PHARMACOKINETICS AND DOSE PROPORTIONALITY STUDY OF SEROQUELTM (ICI 204,636 IN MALE SCHIZOPHRENIC PATIENTS. (ABSTRACT) Y. WJ Wong. BJ Ewing, LF Fabre, PT Thynum & C Yeh. CNP Meeting, San Juan, Puerto Rico, Dec. 11 -15, 1995.
118. BIOEQUIVALENCE OF CLOZAPINE IN HEALTHY SUBJECTS. RG Buice, V. Suramanian, KL Duchin, J. Whisnant, LF Fabre, IVAX Corporation and Fabre Clinics, Inc. (POSTER) AAPS Meeting, Miami, Florida, November 9, 1995.
*119. MULTIPLE DOSE PHARMACOKINETICS AND DOSE PROPORTIONALITY STUDY OF SEROQUEL (ICI, 204,636) IN MALE SCHIZOPHRENIA PATIENTS. Fabre, LF, Wong, James, JC, Ewing, Barbara J, Thyrum Per, Yeh, Chiao (POSTER) presented at the ACNP Annual Meeting in San Juan, Puerto, Rico, Dec. 10-13, 1995.
*120 MULTIPLE DOSE PHARMACOKINETICS OF ICI 204,636 IN SCHIZOPHRENIC MEN AND WOMEN (ABSTRACT) Feigner, A., and Fabre, LF. NCDEU Meeting, Boca Raton, Florida, May 28-31, 1996.
*121. GEPIRONE EXTENDED RELEASE (ER) TREATMENT OF OUTPATIENTS WITH MAJOR DEPRESSION-A DOSE RESPONSE STUDY. COHN, C., FABRE, LF (POSTER) presented at the XX C.I.N.P. Congress Collegium International Neuropsychopharmacologicum Congress, Melbourne, Austrailia, June 23-27, 1996 The Journal of the European Collegte of Neuropsychopharmacology, Volume 6, Supplement 3, June 1996. (Page 49)
122. LONG TERM GEPIRONE EFFICACY IN THE TREATMENT OF MAJOR DEPRESSION PREVENTION OF RELAPSE (ABSTRACT) Fabre, L.F., and Claghorn, J. presented at the NorAge/IPA Congress, Reykjaik, Iceland, October 4-5, 1996.
123. GEPIRONE SAFETY AND EFFICACY IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (ABSTRACT) Fabre, LF. and Kramer, SJ. Presented at the NorAge/IPA Congress, Reykjavik, Iceland, October 4-5, 1996.
124. OVERVIEW TREATMENT RESISTANT DEPRESSION, PSYCHOPHARMACOLOGY• (INCLUDING THE DIFFERENCES SEEN IN THE GERIATRIC POPULATIONS, AUGMENTATION STRATEGIES: THYROID AUGMENTATION, LITHIUM, PSYCHOSTIMULANTS, ESTROGEN, ETC. AND DEPRESSION IN SUBSTANCE ABUSERS, ADOLESCENTS AND OTHER SUBPOPULATIONS Louis F. Fabre, M.D., Ph.D. presented at the Third Annual Psychiatric Symposium: Focus on Depression, Great Falls, Montana, October 11, 1996.
125. STRATEGIES IN THE TREATMENT OF RESISTANT DEPRESSION Louis F. Fabre, M.D., Ph.D., presented at the Menninger Clinic (Seely Conference Center) Topeka, Kansas, Oct. 25-26, 1996.
126. GEPIRONE EXTENDED RELEASE (ER) COMPARED TO PLACEBO IN THE TREATMENT OF OUTPATIENTS WITH MAJOR DEPRESSION. (ABSTRACT) NR562 Cohn C., and Fabre, LF presented at the American Psychiatric Association Meeting, San Diego, CA, May, 1997.
127. CITALOPRAM IN THE TREATMENT OF MODERATE TO SEVERE DEPRESSION. Mendels, J., Kiev, A, Fabre, LF, and Schwartz, G presented at the American Psychiatric Association Meeting, San Diego, CA, May, 1997.
1. Amoxapine Capsules. To evaluate the therapeutic efficacy and side effects of amoxapine in comparison with placebo and imipramine in patients with depressive illness. (Lederle Laboratories)
2. U-33,030 and placebo comparison in patients with insomnia (14 day study). (The UpJohn Company).
3. U-33,030 and placebo comparison in patients with insomnia (2 day study). The UpJohn Company)
4. U-33,030 and flurazepam comparison in patients with insomnia (single-dose cross-over study). (The UpJohn Company)
5. Double-Blind placebo controlled study of U-28,774 in anxiety. (The UpJohn Company)
6. U-33,030 and flurazepam comparison in patients with insomnia (7 day study). (The UpJohn Company)
7. Triazolam and placebo comparison in psychiatric patients with insomnia (single-dose cross-over study). (The UpJohn Company)
8. Triazoilan and placebo comparison in geriatric patients with insomnia (single-dose cross-over study). (The UpJohn Company)
9. Triazolam and placebo comparison in psychiatric patients with insomnia (7 day study). (The UpJohn Company)
10. Triazolam (U-33,030) open label efficacy study in insomniac alcoholic patients after withdrawal from alcohol (28 day study). (The UpJohn Company)
11. Triazolam open label efficacy study in patients with isomnia (7 day study). The UpJohn Company)
12. Triazolam and flurazepam comparison in patients with insomnia (single-dose cross-over study). (The UpJohn Company)
13. Comparison of alprazolam, Valium and placebo in the treatment of anxiety. (The UpJohn Company)
14. Efficacy of Alprazolam in the treatment of anxiety in recovering alcoholic subjects. (The UpJohn Company)
15. Efficacy of alprazolam in the treatment of neurotic depression. (The UpJohn Company). .
16. Comparison of ketazolam, diazepam and placebo in once a day vs. TID dosing. (The UpJohn Company)
17. Open label evaluation of minimum effective dosage and tolerance of graded oral doses of nomifensin in depressed outpatients. (Hoechst)
18. Open-label study to investigate the efficacy of AHR-2277 in the alleviation of anxiety and improvement in everyday functioning in anxious subjects. (A H. Robins Co.)
19. Triazolam and chloral hydrate comparison in-patients with insomnia (single-dose cross over study). (The UpJohn Company)
20. Triazolam and f1urazepam comparison in patients with insomnia. (The UpJohn Company)
21. Comparison of lenperone (AHR-2277), diazepam and placebo, 28-day, double-blind study. (A H. Robins Co.)
22. Double-Blind comparative evaluation of efficacy and safety of specific dose range of oral dose of HOE 984, imipramine and placebo in depressed outpatients. (Hoechst)
23. Double-Blind, comparative evaluation of efficacy and safety of a specific dose range of oral doses of WIN 27,147-2, imipramine and placebo in depreseed outpatients. (Sterling-Winthorop)
24. Comparison of therapeutic effect, tolerance and safety of ketazolam and diazepam administered for six months to outpatients with chronic anxiety neurosis. (The UpJohn Company)
25. Comparison of triazolam and placebo in the treatment of insomnia and anxiety in anxious outpatients. (The UpJohn Company)
26. Comparison of ketazolam, clorazepate dipotassium and placebo in once a day vs. multiple daily dosing. (The UpJohn Company)
27. Open rising dose efficacy/safety study of SCH 12679 in anxiety. (Schering Corp.)
28. Evaluation of trazodone in the treatment of endogenous depression. (Mead-Johnson Pharmaceuticals)
29. Wellbutrin phase II placebo controlled proof of efficacy. Multi-clinic (Burroughs-Wellcome Co.)
30. A comparative clinical trial of ripazepam, diazepam and placebo in the treatment of anxiety states. (Parke-Davis)
31. Comparison of the antianxiety efficacy of alprazolam and chlordiazepoxide hydrochloride in the chronic withdrawal period from alcohol. (The UpJohn Company)
32. Ha1azepam, SCH 12041, an anti-anxiety agent. (Schering Corp.)
33. Alprazolam, imipramine and placebo in the treatment of neurotic depression. (The UpJohn Company)
34. Phase II open study of MCN-3377 to establish efficacy in the treatment of non-psychotic patients with manifest anxiety. (McNeil Laboratories)
35. A 14-28 day efficacy, safety and toleration study of SAH 48-104 to 75 mg BID vs. placebo in hospitalized depressed patients. (Sandoz)
36. The Safety and effectiveness of long term oral administration of trazodone in depressive illness. (Mead-Johnson Pharmaceuticals)
37. Comparison of triazolam, diazepam and placebo in the treatment of insomnia and anxiety in outpatients with anxiety neurosis. (The UpJohn Company)
38. Phase II double-blind controlled study of McN3377 fenobam preparation and placebo to establish efficacy in the treatment of non-psychotic outpatients with manifest anxiety. (McNeil Laboratories)
39. Phase II open label controlled study of nabilone in anxiety. (Eli Lilly and Company)
40. A comparative clinical trial of trenbenzomine, chlordiazepoxide and placebo in the treatment of mixed affective-anxious disorders. (Parke-Davis)
41. Phase II pilot open label study of brofoxine in anxiety. (Adria Labs)
42. Comparison of Halcion and placebo in the treatment of insomnia in depressed patients on tricyclic anti-depressants. (The UpJohn Company)
43. Phase IV outpatient comparison of Prazepam against placebo, diazepam and clorazepate in anxiety. (Warner Chilcott)
44. Evaluation of anti-anxiety and anti-anginal effects of peritrate 80 mg sustained action tablets with phenobarbitol. (Warner Chilcott)
45. Phase II double-blind comparison of WY-23,409 and placebo in depression. (Wyeth-Ayerst Laboratories)
46. Maintenance study of bromperidol in chronic schizophrenia. (Ortho Pharmaceutical Group)
47. Double-blind controlled study of McN-2453 Azepindole preparation and placebo to establish efficacy in the treatment of outpatients with depression. (McNeil Laboratories)
48. A double-blind study of the anxiolytic activity and safety of brofoxine in outpatients using a placebo controlled randomized parallel group design. (Adria Laboratories)
49. Comparison of alprazolam and placebo, the treatment of anxiety. (The UpJohn Company)
50. Double-blind evaluation of the safety and efficacy of two dose ranges of Wellbutrin vs. placebo in depressed outpatients. (Burroughs-Wellcome Co.)
51. Comparison of moban and placebo in the treatment of neurotic depression. (Endo Laboratories)
52. Comparison of alprazolam, oxazepam (Serax) and placebo in the treatment anxiety. (The UpJohn Company)
53. A phase I safety studyof VI-100 in small single doses administrered to human subjects. (Vinoien)
54. A phase I safety study of VI-l00 in maximal single doses administered to humnan subjects. (Vinoxen)
55. A phase I safety study of VI-100 IN multiple doses administered to human subjects over a five day trial period. (Vinoxen)
56. A phase I safety study of VI-200 in small single doses administrered to human subjects. (Vinoxen)
57. Phase I safety study of VI-200 in multiple doses administered to human subjects over a five day trial period. (Vinoxen)
58. Phase I safety study of VI-200 in maximal single dose administered to human subjects. (Vinoxen)
59. Double-blind randomized parallel controlled study of nabilone, diazepam or placebo in patients exhibiting symptoms of anxiety. (Eli Lilly and Company)
60. Safety and efficacy of DL-262 in outpatients with endogenous depression. (Dow Chemical)
61. Outpatient comparison of prazepam against placebo diazepam and clorazepate in anxiety. (Warner Chilcott)
62. A dose ranging study of melperone in anxious patients. (Merrell-National)
63. Evaluation of buspirone as an anti-anxiety agent as compared to diazepam. (Mead-Johnson Pharmaceuticals)
64. A controlled multicenter clinical trial of zometapine in the treatment of major depressive disorders. (Warner LambertlParke-Davis)
65. Comparison of the anti-anxiety efficacy of alprazolam (U-31,889) and chlordiazepoxide hydrocholoride and placebo in the chronic withdrawal period from alcohol. (The UpJohn Company)
66. Double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenics. (Ortho Pharmaceuticals Group)
67. Double-blind comparison of VI-l00 and VI-200 and placebo in the treatment of alcohol withdrawal syndrome in recently admitted alcoholic inpatients. (Vinoxen)
68. A short term clinical study comparing the efficacy and safety of quazepam 15 mg with flurazepam 30 mg and placebo for the treatment of insomnia in hospitalized patients. (Schering Co.)
69. A multicenter controlled clinical trial of trebenzomine, thioridazine and placebo in the treatment of newly admitted schizophrenic inpatients. (Warner-LambertJParke-Davis)
70. Phase I single dose tolerance test of EN-207. (Endo Laboratories)
71. Bioequivalency of kanamycin with the standard kanamycin in normal subjects. (Beecham Laboratories)
72. Phase IV impatient comparision study of prazepam vs. placebo in the treatment of anxiety associated with the acute phase of alcohol withdrawal. (Warner-Lambert)
73. Phase I multiple dose tolerance test of EN-207. (Endo Laboratories)
74. A controlled multicenter clinical trial of vivalan (ICI 58,834) in the treatment of psychogeriatric patients with a clinical diagnosis of endogenous depression. (ICI Pharmaceuticals)
75. Evaluation of buspirone as an anti-anxiety agent, buspirone vs. diazepam. (Mead-Johnson Pharmacueticals) .
76. Alprazolam efficacy in the treatment of schizophrenia symptoms and behavior. (The UpJohn Company)
77. A multicenter, controlled clinical trial of trebenzomine, doxepin and placebo in the treatment of depressed-anxious outpatients. (Warner-Lambert)
78. A controlled study of the treatment of major depressive disorders with fluoxetine HCl. (Eli Lilly and Company)
79. Moban bioequivalency study in outpatient schizophrenics. (Endo Laboratories)
80. A double blind multicenter study to compare the efficacy and safety of fluotracen vs. placebo in depressed patients. (Sandoz)
81. Open label emergency use of nomifensine maleate for the treatment of depression. (Hoechst)
82. Multicenter double-blind randomized parallel comparison of naproxen sodium and a compound of aspirin, phenacetin, caffeine and codeine phosphate in patients with moderate to severe pain due to tennis elbow or frozen shoulder. (Syntex Laboratories)
83. Multicenter double-blind randomized parallel comparison of naproxen sodium and propoxyphene napsylate with acetaminophen in patients with moderate to severe lumbosacral pain, tenosynovitis, fibrositis or spondylitis. (Syntex Laboratories)
84. A phase II short-term efficacy study comparing estazolam with flurazepam and placebo. (Abbott)
85. A double blind comparison of VI-100 with placebo in the treatment of tobacco withdrawal and cigarette craving in outpatients.(Vinoxen)
86. An initial safety and efficacy study or SAH 52-522 vs. placebo in neurotic outpatients. (Sandoz)
87. A long term double blind clinical study comparing the safety and acceptance of quazepam 30 mg with flurazepam 30 mg for the treatment of chronic insomnia in outpatients. (Schering-Plough)
88. Phase IV outpatient comparison study of prazepam once daily vs. three times daily dosage. (Parke-Davis)
89. Double-blind, controlled evaluation of pyrilamine maleate and placebo in insomniac patients suffuring primarily from difficulties falling asleep.
90. Zometapine treatment of depressed outpatients. (Warner-Lamber/Parke-Davis)
91. A multi-clinic double blind parallel study of prailene (Nafronyl) vs. placebo in the alleviation of symptoms associated wilh dementia. (Lipha Chemicals, Inc.)
92. Open label study of zomentapine in the treatment of major depressive disorders. (Warner –Lambert/Parke-Davis)
93. The bioavailability of phenacetin free Fiorinal: a comparison of the tablet and capsule to a reference solution. (Sandoz)
94. Clobamine (RMI 81,182 EF) in the treatment of depression. (Merrill-Dow)
95. Bioavailability of phenacetin free Fiorinalwith codeine. (Sandoz)
96. A multicenter efficacy and safety evaluation of SAH 52-522 vs. diazepam (Valium) and placebo in anxious outpatients. (Sandoz)
97. An inpatient phase II dose ranging study of DL-588. (Merrill-Dow)
98. Buproprion: A determination of abuse liability.
99. Phase I multiple dose double-blind tolerance test of EN-207. (Endo Labroatories)
100. Open trial of lofexidine in inpatients with symptoms of alcohol withdrawal. (Merrill-Dow)
101. Phase II open label multidose study of EN-207 in endogenous depression. (Endo Laboratories)
102. A placebo controlled randomized double-blind trial of lofexidine in inpatients with symptoms of alcohol withdrawal. (Merrill-Dow)
103. Amoxapine and maprotiline in the treatment of depressive illness: A conlrolled comparison in outpatients using the dexomethasone suppression test as a neuroendocrine marker.
104. Multicenter phase II double-blind placebo controlled study of EN-207 in depressed outpatients - utilizing fixed dose ranges. (Endo Laboratories)
105. Phase II open label multiple dose study of EN-207 in depressed patients for six weeks. (Endo Laboratories)
106. Double-blind evaluation of the safety and tolerance of 106-689-2i -multiple doses for seven days in healthy volunteers. (Sandoz)
107. A study of the effect of antacid and anticholinergic medication on ranitidine absorption. (Glaxo, Inc.)
108. An outpatient phase II dose ranging study of napactadine.
109. The steady state bioavailability Mellaril tablets, suspension and concentrate. (Sandoz)
110. Multiple oral dose tolerance study of tracazolate (ICI 136,753) 40 mg QUID in normal subjects. (ICI Pharmaceuticals)
111. Multiple oral dose tolerance study of tracazolate (ICI 136,753) 80 mg QID in normal subjects. (ICI Pharmaceuticals)
112. An open label multicenter study to determine the safety and efficacy of a total daily dose of 6 mg ergoloid mesylares (Hydergine) plus 60 mg nortriptyline HCI (Pamelor) in depressed outpatients. (Sandoz)
113. Multiple oral dose tolerance study of tracazolate (ICI 136,753) 20 mg QID in normal subjects. (ICI Pharmaceuticals)
114. CGS7135A in moderate depression. (Ciba-Geigy)
115. An open label dose-ranging trial of synaptamine outpatients with anxiety neurosis. (Ciba-Geigy)
116. Continued treatment of depressed hypertensive patients who have benefited from trazondone in a clinical trial (Mead Johnson Pharmaceuticals)
117. Comparison of trazondone and amitriptyline in the treatment of depressed patients with stable controlled hypertension. (Mead-Johnson Pharmaceuticals)
118. Amoxapine and maprotiline in the treatment of depressive illness: A controlled comparison in outpatients using dexomethasone suppression test as a neuroendocrine marker.
119. Tolerance to repeated intravenous infusions of ranitidine HCI at two dose levels (Glaxo, Inc.)
120. Phase I/II CP-51,974 in the treatment of depressed inpatients double-blind, multiple dose multicenters protocol. (Pfizer, Inc.)
121. Long-term safety and efficacy of CGS-7135A in moderate depression (humanitarian protocol). (Ciba-Geigy)
122. Synaptamine (CGS-7525A) antidepresseant open label, single vs. multiple dosing trial. (Ciba-Geigy)
123. Long-term safety and efficacy of CGS-7525A in anxiety neurosis. (Ciba-Geigy)
124. Rechallenge of normal subject who developed diarrhea during I.V. administration of ranitidine HCI. (Glaxo, Inc.)
125. The steady state bioavailability of Mellaril sustained realse tablets. (Sandoz)
126. CGS-7575A double-blind trial comparing CGS-7525A with diazepam and placebo in outpatients with anxiety neurosis. (Ciba-Geigy)
127. Tolerance to repeated iniravenous infusions of ranitidine HCI at two dose levels comparison with cimetidine and saline infusions. (Glaxo, Inc.)
128. Double-blind trial comparing CGS-7135A with desigpramine HCI and placebo in patients with moderate depression (Ciba-Geigy)
129. Oxaprotiline Hydrochloride double-blind comparative efficacy and tolerability study with placebo in known alcoholic patients with a depressive episode of moderate severity. (Ciba-Geigy)
130. Long-term use of oxaprotoline hydrochloride in patients with a depressive disorder. (Ciba-Geigy)
131. An open long-term study of sertraline (CP-51,974) in the treatment of depressive illness. (Pfizer, Inc.)
132. CGS-7135A onset of action study in patients with moderate depression. (Ciba-Geigy)
133. Oxaprotiline hydrochloride comparative efficacy and tolerability study with amitriptyline hydrochloride and placebo in major depressive disorder. (Ciba-Geigy)
134. A controlled study of the treatment of generalized anxiety disorder comparing twice a day dosing of lorzafone and diazepam or placebo. (Eli Lilly and Company)
135. CP-529,74 Double-blind (Pfizer, Inc.)
136. Long-term use of oxaprotoline hydrochloride in alcoholic patients with a depressive disorder. (Ciba-Geigy)
137. Comparison of buspirone, alprazolam and lorazepam in the treatment of anxiety. (Mead-Johnson Pharmaceuticals)
138. A double-blind placebo controlled cross-over study to compare two initial dosage regimens of labetalol (Trandate) in patients with mild or moderate hypotension. (Glaxo, Inc.)
139. Multicenter double-blind placebo controlled randomized comparative study of clovoxamine fumarate and imipramine hydrochloride in patients with major depressive episode. (Kali-Duphar)
140. Tomoxetine vs. placebo in depression (parallel: blind). (Eli Lilly and Company)
141. Phase II/III sertraline (CP51-974) in the treatment of patients with major depression (double-blind, multiple dose protocol). (Pfizer, Inc.)
142. Double-blind parallel comparison of citalopram and placebo in patients with major depression or bipolar disorder, depressed. (Pfizer, Inc.)
143. Buspirone in the symptomatic treatment of acute alcohol withdrawal. (Bristol-Myers)
144. Open-label, dose-ranging, safety and efficacy trial of CGS-10746B in subchronic and chronic schizophrenics with acute exacerbations requiring institutionalization. (Ciba-Geigy)
145. A multicenter, double-blind, parallel, placebo-controlled dose ranging study evaluating the safety and efficacy of suriclone in patients with a generalized anxiety disorder. (Ives Laboratories)
146. Double-blind, multiple dose, sertraline/placebo controlled trial in major depressive disorder-protocol extension. (Pfizer, Inc.)
147. Tomoxetine in depression – extension study. (Eli Lilly and Company)
148. Open label, dose-ranging, safety and efficacy trial of CGS-10746B given every 12 hours in subchronic and chronic schizophrenics with acute exacerbations. (Ciba-Geigy)
149. Pharmacokinetics of labetalol (Trandate) in elderly and younger patients with hypertension. (Glaxo, Inc.)
150. Buspirone in the long-term treatment of chronic anxiety. (Mead-Johnson Pharmaceuticals)
151. A multicenter non-blind, dose ranging study evaluating the safety and efficacy of suriclone in patients with generalized anxiety disorder. (Ives Laboratories)
152. Fluvoxamine Maleate: A multicenter placebo-controlled comparison of two dosage regimens in outpatients with major depression. (Kali Duphar)
153. A parallel study to compare the pharmacodynamic profile of lebetalol to that of hydrochlorothiazide in patients with mild to moderate hypertension. (Glaxo, Inc.)
154. MDS-509 A multicenter, two phase, dose ranging study evaluating the safety and efficacy of suriclone in patients with generalized anxiety disorder. (Wyeth-Ayerst Laboratories)
155. CGS-9896 single-blind, dose-ranging trial of BID and TID dosing of CGS-9896 or placebo in outpatients with generalized anxiety disorder. (Ciba-Geigy)
156. Nitrendipine (BAY e 5009) bioequivalency of various formulations in healthy volunteers. (Miles, Inc.)
157. Nilrendipine (BAYe 5(09) bioequivalency of various formulations in healthy volunteers: stale isotope technique. (Miles, Inc.)
158. Fluvoxamine Maleate: A humanitarian protocol for continuation of treatment up to six months. (Kali-Duphar)
159. Fluoxetine in the treatment of major depressive disorder (compassionate use). (Eli Lilly and Company).
160. Clovoxamine in the treatment of anxiety and depression in anxious, depressed outpatients: A multicenter double-blind placebo-controlled randomized comparative study of clovoxamine fumarate and imipramine hydrochloride. (Kali Duphar)
161. A multicenter, double-blind, placebo controlled, fixed-dose response study evaluating the efficacy and safety of minaprine in patients with major depression (Ives Laboratories)
162. A double-blind, imipramine and placebo controlled study of paroxetine in depressed outpatients. (Beecham Laboratories)
163. A multicenter, double-blind, placebo controlled, fixed-dose response study evaluating the efficacy and safety of minaprine in patients with dysthymic disorder. (Ives Laboratories)
164. A multicenter, double-blind, placebo controlled fixed dose evaluation of four doses of paroxetine. (Beecham Laboratories)
165. Minaprine MDS 536,537 extended treatment amendment. (Ives Laboratories)
166. Fluoxetine vs. placebo: Fixed low dose in depression. (Eli Lilly and Company)
167. A double-blind extension of protocol PAR03-04. (Beecham Laboratories)
168. A double-blind extension of protocol PAR03-06. (Beecham Laboratories)
169. Ascending single dose tolerance study of WY-45,030 tablets. (Wyeth-Ayerst Laboratories)
170. Pamelor Study #4-I-OP Comparative evaluation of nortriptyline vs. trazodone in depressed geriatric outpatients. (Sandoz)
171. Double-blind, placebo-controlled, multiple dose tolerance study of WY-45,030 tablets. (Wyeth-Ayerst Laboratories)
172. Tomoxetine/Placebo fixed dose depression. (Eli Lilly and Company)
173. A phase III double-blind, multisite comparison of sertraline and amitriptyline in the treatment of geriatric patients with major depression or bipolar disorder depressed. 36(Pfizer, Inc.)
174. A phase III long term, double-blind, multisite continuation of the comparison of sertraline and amitriptyline in the treatment of geriatric patients with major depression or bipolar disorder depressed. (Pfizer, Inc.)
175. Extension of protocol B4Z-MC-HFA6 tomoxetine/placebo fixed dose depression. (Eli Lilly and Company)
176. Open-label study of WY-45,030 tablets in depressed outpatients. (Wyeth-Ayerst Laboratories)
177. The comparative steady state bioavailability of Mellaril. (Sandoz)
178. Double-blind placebo controlled study in patients with generalized anxiety disorder SL80.0342. (Lorex)
179. An open label multicenter evaluation of the efficacy and safety or orally administered GR-C507/75 inpatients with a generalized anxiety disorder. (Glaxo Inc.)
180. A parallel, dose-blind, placebo-controlled, pilot dose-ranging, multicenter study to evaluate the efficacy and tolerability of BTS 54524 in outpatients with major depression. (The Boots Company)
181. Double-blind, placebo-controlled, parallel-group dosage-determination study of WY-45,030 tablets in depressed patients. (Wyeth-Ayerst Laboratories)
182. Compassionate use of sertraline (CP-51,974) for major depression. (Pfizer, Inc.)
183. Evaluation of ICI 169,369 in patients with generalized anxiety. (Stuart)
184. Intermediate-term safety and clinical acceptability study in WY-45,030 tablets in depressed patients. (Wyeth-Ayerst Laboratories)
185. Double-blind, placebo-controlled, long term study of alpidem in patients with anxiety disorders. (Lorex)
186. A double-blind, multicenter trial of two dose ranges of gepirone vs. placebo in the treatment of depressed outpatients. (Bristol-Myers)
187. Comparison of Buspirone to placebo in major depressive disorder. (Bristol-Myers)
188. The steady state bioequivalence of Mellaril 100 mg, 200 mg, and 400 mg sustained release tablets. (Sandoz)
189. Ascending single dose safety and tolerance study of WY 47,384 capsules. (Wyeth-Ayerst Laboratories)
190. A phase II, parallel-group, p1acebo-controlled study to evaluate the efficacy and safety of ipsapirone HCI in outpatients with generalized anxiety disorder during a four week treatment period. (Miles, Inc.)
191. Double-blind parallel comparison of sertraline and placebo in obese outpatients with mild hypertension. (Pfizer, Inc.)
192. Tomoxetine/placebo modified fixed dose depression. (Eli Lilly and Company)
193. Double-blind parallel comparison of sertraline and placebo in obese patients with mild hypertension -an extension. (Pfizer, Inc.)
194. Extension of protocol B4Z-MC-HFAH tomoxetine/placebo modified fixed dose. (Eli Lilly and Company)
195. Double-blind parallel comparison of SM-3997 and placebo in outpatients with generalized anxiety disorder. (Pfizer, Inc.)
196. Single blind pilot study of SM-3997 in outpatients with generalized anxiety disorder. (Pfizer, Inc.)
197. A double-blind, multicenter trial of two dose ranges of gepirone (1 mg and 5mg) versus placebo in the treatment of anxious outpatients (including long-term extension). (Bristol-Myers)
198. An open-label multicenter trial to evaluate the safety and tolerability of dothiepin in doses of 200-300 mg/day for a 6 week period in patients with depression. (The Boots Company)
199. An open-label, long-term, extension study of dothiepin BPI 1003 study. (The Boots Company)
200. A placebo controlled study to assess a concurrent usage schedule for switching patients from diazepam, clorazepate, or chlordiazepoxide to buspirone. (Bristol-Myers)
201. A placebo-controlled, multicenter evaluation of the efficacy and safety of orally administered GR-C507/75 in (S3A-206) patients with a generalized anxiety disorder. (Glaxo, Inc.)
202. A double-blind, parallel group comparison of idazoxan and placebo in patients with major depressive disorder. (Reckitt & Coleman)
203. A placebo-controlled study to assess a concurrent usage schedule for switching patients from alprazolam to buspirone. (Bristol-Myers)
204. A placebo-colltrolled study to assess a concurrent usage schedule for switching patients from lorazepam to buspirone. (Bristol Myers)
205. A multicenter, randomized, double-blind parallel group dose response study of milacemide in patients with mood disorders currently in a mojor depressive episode. (Searle)
206. An open-label extension study of milacemide in patients with mood disorders currently or recently in a major depressive episode. (Searle)
207. A placebo-controlled, dose response multicenter evaluation of the safety and efficacy of orally administered GR-C507/75 in patients with generalized anxiety disorder. (Glaxo, Inc.)
208. Dose finding study of the efficacy and safety of moclobemide compared with placebo in the treatment of outpatients with major depressive disorder. (Hoffman LaRoche)
209. A double-blind, parallel group, multicenter study to evaluate antidepressant efficacy, safety and tolerability of dothiepin, doxepin and placebo in outpatients with major depression. (The Boots Company)
210. A multicenter, double-blind, placebo controlled trial of CP-76, 593 in the treatment of outpatients with a major depressive disorder. (Pfizer, Inc.)
211. Milacemide dose response study in major depressive episode. (Searle)
212. Double-blind, placebo-controlled, parallel grouop dose determination study of enciprazine tablets in anxious patients. (Wyeth-Ayerst Laboratories)
213. A double-blind trial of nefazodone, imipramine, and placebo in the treatment of depressed outpatients. (Bristol-Myers)
214. A multicenter, double-blind, placebo-controlled, parallel group study of the efficacy of ipsapirone HCI (Bay Q 7821) in outpatients with generalized anxiety disorder. (Miles, Inc.)
215. Double-blind, placebo-controlled , parallel-group dosage-determination study of low doses of vanlafaxine in depressed patients. (Wyeth-Ayerst Laboratories)
216. A multicenter, double-blind, placebo-controlled, parallel group comparison study of the safety and efficacy of ipsapirone HCI (Bay Q 7821) versus placebo in outpatients with major depressive disorder (Miles, Inc.)
217. Etoperidone: Efficacy and safety in outpatients with major depression. (McNeil Pharmaceuticals)
218. A double-blind, p1acebo controlled, comparative trial of sertraline and fluoxetine in the treatment of outpatients with major depressive disorder. (Pfizer, Inc.)
219. Multicenter, placebo-controlled, double-blind study of ICI 170,809 in non-hospita1ized patients with depression. (Stuart)
220. A double-blind, randomized comparison of Pamelor (nortriptyline HCI) with fluoxetine HCCI in subjects with major depressive disorder. (Sandoz)
221. Ascending single dose safety and tolerance study of LAD 2691. (Delegrange)
222. A double-blind multicenter trial of gepirone, imipramine and p1acebo in the treatment of depressed outpatients. (Bristol-Myers)
223. Pilot safety, tolerability and plasma level evaluation of ICI 204,636 in hospitalized patients with schizophrenic symptomatology. (ICI Pharmaceuticals)
224. An open multi-center trial of buspirone in the long term treatment of depressed outpatients. (Bristol-Myers)
225. Clinical protocol: BPI 1009 (dothiepin versus doxepin). (The Boots Company)
226. Tomoxetine/desipramine/placebo trial in major depressive disorder. (Eli Lilly and Company)
227. Long term extension of a double-blind, placebo-controlled, parallel-group dosage determination study of low doses of venlafaxine in outpatients with major depression. (Wyeth-Ayerst Laboratories)
228. Double-blind comparison of 3 doses of SM-3997 and placebo in outpatieuts with major depression. (Pfizer, Inc.)
229. Ascending single dose safety, tolerance and preliminary pharmacokinetic study of WY 47,846 tablets in normal male volunteers. (Wyeth-Ayerst Laboratories)
230. A double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of sibutramine hydrochloride (5, 10 and 20 mg daily) versus desipramine HCI (150 mg daily) in outpatients with major depression. (The Boots Company)
231. F1uvoxamine in the treatment of depression: A single center double-blind placebo-controlled comparison with imipramine in outpatients. (Reid-Rowell)
232. Ascending multiple oral dose safety and tolerance study of LAD 2691 in normal subjects. (Delagrange)
233. A second multicenter double-blind dose response study of zacopride and placebo in anxious outpatients. (Wyeth-Ayerst Laboratories)
234. Efficacy and safety of SC-48274 at 1 mg or 25 mg BID in generalized disorder. (Searle)
235. Open pilot, multicenter, safety and efficacy evaluation of ICI 204,636 in hospitalized patients with acute psychotic symptomatology. (ICI Pharmaceuticals)
236. Open-label eva1uation of WY 47,846 hydrochloride tablets in outpatients with major depression. (Wyeth-Ayerst Laboaratories)
237. Open-label eva1uation of WY 47,846 hydrochloride tablets in outpatients with generalized anxiety disorder. (Wyeth-Ayerst Laboratories)
238. A double-blind, placebo-controlled, TID dose determination study of WY 47,846 hydrochloride tablets in outpatients with gerneralized anxiety disorder. (Wyeth-Ayerst Labroatories)
239. Double-blind, placebo-contorlled, TID dose determination study of WY 47,846 hydrochloride tablets in outpatients with major depression (Wyeth-Ayerst Laboraotries)
240. Double-blind, placebo-controlled, dose ranging evaluation of ondansetron (GR 38032F) versus diazepam in the treatment of generalized anxiety disorder. (Glaxo, Inc.)
241. A second multicenter, donble-blind dose response study of zacropride and placebo in anxious patients. (Wyeth-Ayerst)
242. Double-blind parallel comparison of three dose ranges of CGS-18102A versus placebo in patients with major depressive disorder. (Ciba-Geigy)
243. Ascending single dose safely, tolerance, and preliminary pharmacokinetic study of WY-50,324 hydrochloride capsules in normal male volunteers. (Wyeth-Ayerst)
244. A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder (Smith-Kline)
24. Disposition and metabolism of radiolabeled ICI 204,636 in patients with schizophrenic symptomatology. (ICI Pharmaceuticals)
246. Ascending single-dose safety, tolerance, and preliminary pharmacokinetic study of WY 47,791 hydrochloride capsules in normal male volunteers. (Wyeth-Ayerst)
247. A prospective randomized, double-blind, placebo-controlled, multicenter, parallel-groups comparison of the efficacy and safety of abecarnil low dose (7.5 mg.), high dose (15 mg) , and diazepam (21 mg) in outpatients with gernalized anxiety disorder. (Sandoz)
248. An open, multI-center trial of gepirone extended-release in the treatment of patients with mood disorders. (Bristol-Myers Squibb)
249. A phase I, double-blind, placebo-controlled study of safety, tolerance, and pharmacokinetics of single and multiple doses of RP-62203 capsules in healthy male volunteers. (Rhone-Poulenc Rorer)
250. Double-blind, placebo-controlled, parallel-group dosage determination study of BID and TID doses of venlafaxine in outpatients with major depression. (Wyeth-Ayerst)
251. A prospective randomized, double-blind, placebo-controlled, multicenter, parallel-groups comparison of the efficacy and safety of abecarnil (3.0-9.0 mg) and lorazepam (1.5-4.5 mg) in elderly outpatients with anxiety symptoms. (Sandoz)
252. A prospective multicenter, open-label study of the safety of abecarnil (5.0-17.5 mg) in outpatients with genemlized anxiety disorder. (Sandoz)
253. A double-blind, placebo-controlled, multicenter trial comparing 30 mg of BuSpar given two times daily versus three times daily in patients with generalized anxiety disorder. (Bristul-Myers Squibb)
254. A multicenter evaluation ofthe safety and efficacy of 150 mg/day and 300 mg/day of Bupropion HCI sustained-release versus placebo in depressed outpatients. (Burroughs-Wellcome Co.)
255. LY237733 in patients with genemlized anxiety disorder. (Lilly)
256. LY170053 versus placebo/haloperidol in the treatment of schizophrenia. (Lilly).
257. A study of the efficacy of 4mg and 8 mg of HP873 administered to schizophrenic patients for 42 days. (Hoechst-Roussel)
258. Safety surveillance study fur Wellbutrin sustained release (Burroughs Wellcome Co.)
259. Fixed Dose Olanzapine versus Placebo in the Treatment of Schizophrenia (Lilly)
260. A multicenter, double-blind, randomized, controlled, multiple fixed-dose and dose regiment comparison of Seroquel (TM) (ICI 204,636) and Haloperidol in the prevention of psychotic relapse in outpatients with chronic or subchronic schizophrenia. (Zeneca Pharmaceuticals)
261. FID-MD-HGAP-Fixed Dose Olanzapine Versus Placebo in the Treatment of Schizophrenia (Lilly Research Laboratories)
262. A multicenter evaluation of the safety and efficacy of two flexible doses of Wellbutrin 7 sustainedrelease versus placebo in depressed outpatients (Burroughs Wellcome Company)
263. Forty-week, double-blind study evaluating the safety and efficacy of two dose regiments of oral ziprasidone (GP-88, 059-1 (80-120mg, QD, and 40-80mg, BID) and haloperidol (5-20mg daily) in the maintenance treatment of outpatients with schizophrenia or schizoaffective disorder (Pfizer)
264. A clinical evaluation of Risperdal (TM) in the treatment of schizophrenia (Parexel Int. Corp.)
265. A study for the evaluation of safety, tolerlance and steady-state pharmacokinetics of HP 873 up to 16mg/day administered to hospitalized schizophrenic patients (Hoechst-Roussel Pharmaceuticals, Inc.)
266. Phase III, six week, double-blind, multicenter, placebo controlled study evaluating the efficacy and safety of two oral fized doses of oral ziprasidone CP-88, 059-1 (40 mg, BID and 80 MG, BID) in the acute exacerbation of schizophrenia and schizoffective disorder (Pfizer)
267. A single-dose, two-way crossover evaluation to determine the bioavailability of a trifluoperazine HCL tablet, 10 mg, (Stelazine, J, SKB) and trifluoperazine HCL tablet, 10 mg, (Invamed) in a test population of 38 healthy fasted male volunteers (Invamed, Inc.)
268. Flesinoxan in the treatment of generalized anxiety disorder. A single-center, double-blind, parallel, placebo controlled comparison with diazepam in outpatients. (Solvay)
269. A 156 week (3 year) Open extension study evaluating the safety and outcome of 40-200 mg, daily of oral Ziprasidone or 1-8 BID of oral Ziprasidone daily in the treatment of subjects who have participated in previous Ziprasione (CP-88-0591-1) Clinical Trials. (Pfizer)
270. Effect of ICI 205,636 (Seroquel J) on Antipyrine Metabolism in Subjects with Psychotic Disorders (Zeneca)
271. Bioeqnivalency of Clozapine Tablets 25 mg (Zenith)
272. A multiple-dose, steady-state study assessing the relative bioequivalence of Clozapine (Zenith Laboratories, Inc.) and Clozaril 7 (Sandoz). (Zenith)
273. An eight subject pilot study assessing the negative bioequivalence of Clozapine (Zenith Laboratories) and Clozaril 7 (Sandoz). (Zenith)
274. Acute bioequivalence study with 200 mg tablet formulation of Fluconazole in fasted health normal men. (Novophram Limited)
275. A bioeqnivalence trial comparing ICI 204,636 (Seroquel J) sales tablets (1 x 200 mg.) and ICI 204,636 clinical trial tablets (2 x 100 mg) in men with selected psychotic disorders. (Zeneca)
276. A multicenter, multinational, double-blind, dose-rising placebo-controlled study of Fananserine in inpatients with schizophrenia. (Rhone-Poulenc Rorer)
277. Bioequivalence of clozapine tablets 25 mg in schizophrenic subjects. (Novopharm)
278. A prospective, randomized, multi-center, double-blind, parallel-group study of the efficacy and safety of SDZ-MAR 327 (200-400) mg/day) as compared to haloperidol (10-20mg/day) and placebo in institutionaliezed patients with chronic schizophrenia. (Sandoz)
279. Double-blind, placebo-controlled study of Venlafuxine ER and Fluoxetine in outpatients with major depression. (Wyet Ayerst Laboratories)
280. Single doso two-way crossover bioequivalence study of Invamed, Clomipiamine hydrochloride 25 mg capsules and anafraril 7 25 mg in healthy male volunteers. (Invamed)
281. Phase III, six week, double blind, multicenter placebo-controlled study of evaluating the efficacy and safety of three fixed doses of oral Ziprasidone (20 mg, BID, 60 mg, BID and 100 mg, BID) and Haloperidol in the acute exacerbation of schizophrenia and schizoaffective disorder. (Pfizer)
282. Mazapertine dose-finding trial, comparing three fixed doses of Mazapertine to Risperidone and placebo: Multicenter, double blind, parallel group study. (Janssen)
283. The tolerability and safety of switching to and subsequently withdrawing from ICI 204,636 (Seroquel) in subjects with selected psychotic disorders. ( Zeneca)
284. A two-way single-dose, fasting bioavalability study of Clozapine 25 mg given as a 12.5 mg dose in normal healthy-male-volunteers (Novopharm)
285. The Pharmacokinetics, Tolerability and Safety of ICI 204,636 (Seroquel ™ When Co-administrered with Fluoxetine or Imipramine in Subjects with Selected Pschotic Disorder (Zeneca)
286. A Phase II, Multicenter Double Blind Parallel Randomized Comparison of Oral Fananserin and Placebo over 28 days in impatients with Schizophrenia (Rhonme-Poulenc)
287. Open Label Trial for ICI 204,636 (Seroquel) (Zeneca)
288. Double-Blind Placebo Controlled Study of Venlafaxine and Fluoxetine in patients with Major Depresion and Melancholia (Wyeth-Ayerst)
289. Bioequivalence of Clozapine Tablets 25 mg in Schizophrenia patients (Novopharm)
290. A Pilot Two Way Single Dose, Food Effect, Comparative Bioavailability Study of Nifedinpine ER Tablets (30 mg) versus Adalat CC Tablets (30 mg) in twelve Normal, Healthy, Non-Smoking Male Volunteers (Biovail Corporation International)
291. A Multicenter Double-Blind Placebo Controlled Caparison of the Effects on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release and Sertraline in Outpatients with Moderate to Severe Recurrent Major Depression (Glaxo Wellcome)
292. A pilot bioavailablity study with a single 75 mg talet of Permoline (Cylett) in fasted healthy, normal men. (Biossay Laboratory Inc.)
293. A relative bioavailabli1ty pilot study of bupriopion HCL 100 mg tablets under fasting conditions. (Glaxo Wellcome) (Bioassay)
294. Compatative single dose Bioequivalence study of Clozapine tablets in schizophrenic patients (Mylan Pharmaceuticals, Inc.)
295. A relative bioavailability pilot study of Omeprazole 20 mg delayed-release capsules. (Vigi Hyuma, Ph.D.)
296. Tolerabilty and pharmacokinetics of once daily dosing of quetiapine (Seroquel TM) in men and women with selected psychotic disorders (Zeneca)
297. Strategies for switching from conventional antipsychotic drugs to Olanzapine (Eli Lilly Company)
298. Risperidone vs. Olanzapine in the treatment of Schizophrenia (Janssen Reserach Foundation)
299. Risperiodone vs. Olanzapine in the treatment of Schizophrenia (Janssen Research Foundation)
300. A Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR 46349B in outpatients with Major Deprssion. (Sanofi)
301. A Phase III double-blind placebo controlled study of Aripiprazde in the treatment of Psyhosis, with Risperidone as active control.
302. An open-label follow up study of the long term safety of Aripiprazole in patients with psychosis (Otsuka)
303. Double-blind placebo controlled 14 day treatment study of the safety and tolerability of SR 48692 in patients with Schizophrenia (Sanofi)
304. A Multi-center, placebo-controlled study of Wellbutrin (Bupropion Hydrochloride) sustained release (2R) for the prevention relapse recurrence in subjects whose depression responded to treatment with Wellbutrin SR. (Glaxo Wellcome)
305. Olanzapine alone and in corporation with Fluoxetine versus placebo in Major Depressive disorder with psychotic features. (Eli Lilly)
306. Multi-center, open label, long-term follow-up safety study of M100907 tablets in Schizophrenia and Schizoaffective subjects who participated in Protocol M100907/3001 or M100907/3002 (Hoechst Marion Roussel)
307. A multi-center, placebo and active control double-blind randomized study of the efficacy and safety of M100907 (10 and 20 mg/day) in schizophrenics and schizoaffective patients (Hoechst Marion Roussel)
308. The pharmacokinetics of Geppar 20 mg MR tablets (Sidmak) in male Asians compared to male Caucasians and males of African Descent (Blacks). (Fabre-Kramer Pharmaceuticals, Inc.)
309 Effect of Food on the bioavailability of Geppar 20 mg MR Tablets (Sidmak). (Fabre-Kramer Pharmaceuticals, Inc.)
310. Bioequivalence of Bristol-Myers Squibbs Gepirone 20 mg ER tablets and Fabre-Kramer Pharmaceuticals, Inc. Geppar 20 mg MR tablets (Sidmak). (Fabre-Kramer Pharmaceuticals, Inc.)
311. Olanzapine versus Placebo in the treatment of bipolar disorder, manic or mixed.
312. A pilot study to evaluate the pharmacokinetic profile after a single dose (1 x 20 mg) of Geppar MR (Sidmak) tablets in healthy male volunteers under fasting and non fasting conditions. (FabreKramer Pharmaceuticals, Inc.)
313. Multiple-dose Pharmacokinetics and the Effect of Food in Sustained-Release (SR) Quetiapine Fumarate (Seroquel) (Zeneca Pharmaceuticals)
314. An Open Label Comparison of the Neurocognitive Effects of Aripiprazole to Olazapine Administrered Orally in Patients With Stable Psychosis (Otsuka Pharmaceuticals)
315. An Open-Label Follow-up Study of the Long-Term Safety of Aripiprazole Administered Orally in Patients with Pschosis (Otskuka Pharmaceuticals)
316. A Multi-Center, Double-Blind, P1acebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (bupropion HCI) Sustained Release (SR) Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression (Glaxo Wellcome)
317. Rising Single and Mutliple Dose Tolerance Study of DAB-452 in Patients with Schizophrenia and Schizoaffective Disorder (Wyeth Ayerst Pharmaceuticals)
318. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 7-Week Evaluation of the Efficacy and Safety of Lamotrigene in Treatment of a Depressive Episode in Unipolar Depressed Patients (Glaxo Wellcome Pharmaceuticals)
319. The Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Alprazolam Given Before and During Treatment with Quetiapine Fumarate (SEROQUELTM) in Men and Women with Selected Psychotic Disorders (Zeneca Pharmaceuticals)
320. A Placebo-Controlled Study of Pregabalin in Patients with Acute Mania (Parke-Davis Pharmaceuticals)
321. Striatal Dopamine-D2 Receptor Binding of DAB-452 Using Positron Emission Tomography (PET) in Patients witil Schizophrenia or Schizoaffective Disorder (Wyeth Ayerst Pharmaceuticals)
322. A Multi-center, Randomized, Double-blind, Active-Controlled Study to Compare the Long-term Maintenance Effects and Safety of Aripiprazole and Haloperidol Following Acute Relapse in Schizophrenic Patients (Otsuka America Pharmaceuticals, Inc,)
323. An Open-Label Follow-up Study of the Long-Term Safety of Aripiprazole in Patients with Chronic Schizophrenia (Otsuka America Pharmaceuticals, Inc,)
324. A Usual Use, Open Label, Randomized, 3 Month Cohort, Outcomes Study in Persistent Back Pain Comparing OxyContin® Q12H (Controlled Release Oxycodone) vs. Hydrocodone/APAP Q4-6 PRN (Purdue Pharma, L,P,)
325. A Three Year, Open Label, Analgesic Efficacy, Safety, Acceptability, Tolerability and Quality of Life Registry of Controlled Release Oxycodone Tablets (OxyContin®) in Chronic Non-Cancer Pain (Purdue Pharma, L,P,)
326. Prevalence of Hyperprolactinemia in Schizophrenic Patients Treated With Antipsychotic Drugs (Eli Lilly and Company)
327. Olanzapine in the Reduction of Hyperprolactinemia and Associated Morbidity in Schizophrenic Patients (Eli Lilly and Company)
328. Allelic Variation in Schizophrenia (Eli Lilly and Company)
329. A Study to Examine the Tolerance and Pharmacokintetics of Short-Acting Intramuscular Olanzapine in Patients with Chronic Schizophrenia (Eli Lilly and Company)
330. Risperidone depot (microspheres) in the treatment of subjects with schizophrenia or schizoaffective disorder. (Janssen Research Foundation)
331. Double-Blind, Placebo-Controlled, Comparative Efficacy Study of Venlafaxine ER and Sertraline in Producing Remission in Outpatients with Major Depressive Disorder (Wyeth-Ayerst Research)
332. A Multicenter, parallel, double-blind, placebo controlled, randomized comparison of a flexible dose of GW650250A (8 to 16 mg) and placebo for the outpatient treatment of moderate to severe recurrent depression. (GlaxoWellcome)
333. A Double-Blind, Placebo and Paroxetine Controlled, Multicenter, Dose-Ranging Study Evalualing the Efficacy and Safety of SR142801 in Outpatielits with Major Depressive Disorder (Sanofi-Synthelabo)
334. Placebo-Controlled Olanzapine Monotherapy in the Treatment of Bipolar I Depression (Eli Lilly and Company)
335. A Controlled Trial of the Efficacy of Rapid Initial Dose Escalation of Olanzapine to Treat Acute Behavioral Agitation in Schizophrenia and Bipolar I Disorder (Eli Lilly and Company)
336. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of SEROQUELTM (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania (AstraZeneca)
337. Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of Major Depression (Eli Lilly and Company)
338. A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Extended-Release Carbamazepine in Patients with Bipolar Disorder (Shire Laboratqries)
339. A Six-Month, Open Label, Multicenter Study of Extended-Release Carbamazepine in Patients With Bipolar Disorder -An Extension of Protocols 105.301 and 105.302 (Shire Laboratories)
340. A Double-Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR46349B in Schizophrenic Patients (Sanofi-Synthelabo)
341. A Double-Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR48692 in Schizophrenic Patients (Sanofi-Synthelabo)
342. A Multi-Center, Randomized, Double-Blind, Active-Controlled Study to Compare the Long-Term Maintenance Effects and Safety of Aripiprazole and Haloperidol Following Acute Relapse in Schizophrenic Patients (Otsuka America Pharmacenticals)
343. An Open-Label, Follow-on Study of the Long-Term Safety of Ariprazole in Patients with Chronic Schizophrenia (Otsuka America Pharmaceuticals)
344. A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of an Intramuscular Formulation of Depot Olanzapine (Pamoate Salt) in Stable Schizophrenic Subjects (Eli Lilly and Company)
345. The efficacy and safety of single dosage ranges of risperidone vs placebo in the treatment of manic episode associated with Bipolar I Disorder. (Janssen Research Foundation)
346. A 9-week, open-label, multi-center, safety trial of flexible dose ranges of risperidone in the treatment of manic episodes associated with Bipolar I Disorder. (Janssen Research Foundation)
347. A Multicenter, Double-Blind, Randomized Comparison of the Efficacy and Safety of Sustainedrelease Formulation Quetiapine Fumarate (SEROQUELTM) and Placebo in the Treatment of Patients with Schizophrenia (AstraZeneca Pharmaceuticals)
348. A Multiple-Dose Steady-State Study Assessing the Relative Bioequivalence of Clozapine (Zenith Goldline Pharmaceuticals) and Clozaril® 100 mg (Novartis) Tablets (Zenith Goldline Pharmaceuticals)
349. The Assessment of Sibutramine for the Treatment of Olanzapine-Associated Weight Gain in Patients with Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder (Eli Lilly and Company)